[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$flwY_2STbNMj8ayruQnBJgW8cdOY4LkMNNP82uSkfGAA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":81,"rows":88},"Otsuka Pharmaceutical Co., Ltd.",[4],143,false,16,65,31754,15,1,[14,17,20,22,24,27,29,32],{"name":15,"count":16},"Schizophrenia",11,{"name":18,"count":19},"Parkinson's Disease",6,{"name":21,"count":19},"Major Depressive Disorder",{"name":23,"count":19},"Atopic Dermatitis",{"name":25,"count":26},"Acute Myeloid Leukemia",5,{"name":28,"count":26},"Dry Eye Syndromes",{"name":30,"count":31},"Bipolar I Disorder",4,{"name":33,"count":31},"Migraine",[35,40,45,50,55,59,64,69,73,78],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT04649073","Safety and Efficacy Study of OPC-415 in Patients With Relapsed and\u002For Refractory Multiple Myeloma","2025-04-09","OPC-415",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05326347","A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia","2025-08","OPC-34712FUM\u002F Brexpiprazole fumarate",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT05712746","Samtasu Post-marketing General Drug Use-results Survey in Patients with Volume Overload in Heart Failure.","2025-11-30","Samtasu for I.V.",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT03906695","Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes","2026-01-31","ASTX727",{"nctId":56,"briefTitle":57,"date":58,"intervention":44},"NCT05325645","Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia","2026-02",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT05342493","Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use","2026-09-30","Fremanezumab 225 Mg\u002F1.5 mL Subcutaneous Solution",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT07173478","A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis","2026-12","OPA-15406",{"nctId":70,"briefTitle":71,"date":72,"intervention":68},"NCT07184645","A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis","2027-02",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT07086313","A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD","2027-08","EB-1020 (Centanafadine) low dose",{"nctId":79,"briefTitle":80,"date":76,"intervention":77},"NCT07087327","A Long-term Trial of EB-1020 in Pediatric Patients With ADHD",[82,83,84,85,86,87],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[89,149,190,218,240,262,295,317,341,362,383,460,526,548,569,595,683,732,780,798,935,1034,1088,1139,1186,1228,1269,1311,1352,1391,1413,1449,1471,1505,1540,1562,1584,1606,1632,1650,1668,1693,1720,1738,1756,1774,1799,1817,1835,1853,1876,1894,1916,1937,1955,1979,2017,2050,2068,2086,2110,2128,2156,2174,2192,2210,2234,2252,2277,2295,2313,2338,2356,2381,2399,2422,2440,2463,2487,2505,2523,2541,2559,2585,2603,2628,2650,2668,2693,2714,2738,2762,2780,2798,2821,2843,2861,2879,2897,2915,2939,2957,2980,2998,3023,3048,3066,3084,3109,3127,3145,3167,3194,3212,3230,3248,3274,3298,3323,3349,3375,3404,3422,3440,3458],{"intervention":68,"totalTrials":26,"cells":90},{"EARLY_PHASE1":91,"PHASE1":94,"PHASE2":96,"PHASE3":117,"PHASE4":145,"NA":147},{"trials":92,"activeCount":93},[],0,{"trials":95,"activeCount":93},[],{"trials":97,"activeCount":93},[98,109],{"nctId":99,"briefTitle":100,"status":101,"phases":102,"primaryCompletion":103,"completion":103,"start":104,"enrollment":105,"conditions":106,"interventions":107},"NCT03018691","Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis","COMPLETED",[84],"2017-06","2017-01",73,[23],[68,108],"Placebos",{"nctId":110,"briefTitle":111,"status":101,"phases":112,"primaryCompletion":103,"completion":103,"start":113,"enrollment":114,"conditions":115,"interventions":116},"NCT02914548","Study of OPA-15406 Ointment in Patients With Atopic Dermatitis",[84],"2016-09",200,[23],[68],{"trials":118,"activeCount":144,"soonestReadout":67},[119,128,138],{"nctId":65,"briefTitle":66,"status":120,"phases":121,"primaryCompletion":67,"completion":67,"start":122,"enrollment":123,"conditions":124,"interventions":126},"NOT_YET_RECRUITING",[85],"2025-10",156,[125],"Atopic Dermatitis (AD)",[68,127],"Vehicle",{"nctId":129,"briefTitle":130,"status":101,"phases":131,"primaryCompletion":132,"completion":133,"start":134,"enrollment":135,"conditions":136,"interventions":137},"NCT05372653","A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis",[85],"2022-12-29","2023-11-29","2022-05-23",41,[125],[68],{"nctId":70,"briefTitle":71,"status":120,"phases":139,"primaryCompletion":72,"completion":72,"start":140,"enrollment":141,"conditions":142,"interventions":143},[85],"2025-09",198,[125],[68,127],2,{"trials":146,"activeCount":93},[],{"trials":148,"activeCount":93},[],{"intervention":44,"totalTrials":150,"cells":151},3,{"EARLY_PHASE1":152,"PHASE1":154,"PHASE2":166,"PHASE3":168,"PHASE4":186,"NA":188},{"trials":153,"activeCount":93},[],{"trials":155,"activeCount":93},[156],{"nctId":157,"briefTitle":158,"status":101,"phases":159,"primaryCompletion":160,"completion":161,"start":162,"enrollment":163,"conditions":164,"interventions":165},"NCT06036108","Food Effect Study of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia",[83],"2025-03-18","2025-04-08","2023-10-03",59,[15],[44,44],{"trials":167,"activeCount":93},[],{"trials":169,"activeCount":144,"soonestReadout":43},[170,177],{"nctId":41,"briefTitle":42,"status":171,"phases":172,"primaryCompletion":43,"completion":140,"start":173,"enrollment":174,"conditions":175,"interventions":176},"ACTIVE_NOT_RECRUITING",[85],"2022-05-31",190,[15],[44],{"nctId":56,"briefTitle":57,"status":178,"phases":179,"primaryCompletion":58,"completion":180,"start":181,"enrollment":182,"conditions":183,"interventions":185},"RECRUITING",[85],"2026-03","2022-07-21",450,[184],"Acute Schizophrenia",[44],{"trials":187,"activeCount":93},[],{"trials":189,"activeCount":93},[],{"intervention":77,"totalTrials":144,"cells":191},{"EARLY_PHASE1":192,"PHASE1":194,"PHASE2":196,"PHASE3":198,"PHASE4":214,"NA":216},{"trials":193,"activeCount":93},[],{"trials":195,"activeCount":93},[],{"trials":197,"activeCount":93},[],{"trials":199,"activeCount":144,"soonestReadout":76},[200,208],{"nctId":74,"briefTitle":75,"status":178,"phases":201,"primaryCompletion":76,"completion":76,"start":202,"enrollment":203,"conditions":204,"interventions":206},[84,85],"2025-09-03",315,[205],"Attention-Deficit Hyperactivity Disorder(ADHD)",[77,207],"EB-1020 (Centanafadine) high dose",{"nctId":79,"briefTitle":80,"status":178,"phases":209,"primaryCompletion":76,"completion":76,"start":210,"enrollment":211,"conditions":212,"interventions":213},[85],"2025-09-16",180,[205],[77,207],{"trials":215,"activeCount":93},[],{"trials":217,"activeCount":93},[],{"intervention":207,"totalTrials":144,"cells":219},{"EARLY_PHASE1":220,"PHASE1":222,"PHASE2":224,"PHASE3":226,"PHASE4":236,"NA":238},{"trials":221,"activeCount":93},[],{"trials":223,"activeCount":93},[],{"trials":225,"activeCount":93},[],{"trials":227,"activeCount":144,"soonestReadout":76},[228,232],{"nctId":74,"briefTitle":75,"status":178,"phases":229,"primaryCompletion":76,"completion":76,"start":202,"enrollment":203,"conditions":230,"interventions":231},[84,85],[205],[77,207],{"nctId":79,"briefTitle":80,"status":178,"phases":233,"primaryCompletion":76,"completion":76,"start":210,"enrollment":211,"conditions":234,"interventions":235},[85],[205],[77,207],{"trials":237,"activeCount":93},[],{"trials":239,"activeCount":93},[],{"intervention":127,"totalTrials":144,"cells":241},{"EARLY_PHASE1":242,"PHASE1":244,"PHASE2":246,"PHASE3":248,"PHASE4":258,"NA":260},{"trials":243,"activeCount":93},[],{"trials":245,"activeCount":93},[],{"trials":247,"activeCount":93},[],{"trials":249,"activeCount":144,"soonestReadout":67},[250,254],{"nctId":65,"briefTitle":66,"status":120,"phases":251,"primaryCompletion":67,"completion":67,"start":122,"enrollment":123,"conditions":252,"interventions":253},[85],[125],[68,127],{"nctId":70,"briefTitle":71,"status":120,"phases":255,"primaryCompletion":72,"completion":72,"start":140,"enrollment":141,"conditions":256,"interventions":257},[85],[125],[68,127],{"trials":259,"activeCount":93},[],{"trials":261,"activeCount":93},[],{"intervention":263,"totalTrials":144,"cells":264},"EB-1020 (Centanafadine) 164.4 mg",{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":271,"PHASE4":291,"NA":293},{"trials":266,"activeCount":93},[],{"trials":268,"activeCount":93},[],{"trials":270,"activeCount":93},[],{"trials":272,"activeCount":144,"soonestReadout":277},[273,283],{"nctId":274,"briefTitle":275,"status":178,"phases":276,"primaryCompletion":277,"completion":277,"start":278,"enrollment":211,"conditions":279,"interventions":281},"NCT06926829","A Long-term Trial of EB-1020 in Adult Patients With ADHD",[85],"2027-12","2025-06-25",[280],"Attention Deficit Hyperactivity Disorder (ADHD)",[263,282],"EB-1020 (Centanafadine) 328.8 mg",{"nctId":284,"briefTitle":285,"status":178,"phases":286,"primaryCompletion":277,"completion":277,"start":287,"enrollment":288,"conditions":289,"interventions":290},"NCT06931080","Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients",[84,85],"2025-04-30",630,[280],[263,282],{"trials":292,"activeCount":93},[],{"trials":294,"activeCount":93},[],{"intervention":282,"totalTrials":144,"cells":296},{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":301,"PHASE3":303,"PHASE4":313,"NA":315},{"trials":298,"activeCount":93},[],{"trials":300,"activeCount":93},[],{"trials":302,"activeCount":93},[],{"trials":304,"activeCount":144,"soonestReadout":277},[305,309],{"nctId":274,"briefTitle":275,"status":178,"phases":306,"primaryCompletion":277,"completion":277,"start":278,"enrollment":211,"conditions":307,"interventions":308},[85],[280],[263,282],{"nctId":284,"briefTitle":285,"status":178,"phases":310,"primaryCompletion":277,"completion":277,"start":287,"enrollment":288,"conditions":311,"interventions":312},[84,85],[280],[263,282],{"trials":314,"activeCount":93},[],{"trials":316,"activeCount":93},[],{"intervention":318,"totalTrials":12,"cells":319},"SEP-363856",{"EARLY_PHASE1":320,"PHASE1":322,"PHASE2":324,"PHASE3":326,"PHASE4":337,"NA":339},{"trials":321,"activeCount":93},[],{"trials":323,"activeCount":93},[],{"trials":325,"activeCount":93},[],{"trials":327,"activeCount":12,"soonestReadout":332},[328],{"nctId":329,"briefTitle":330,"status":178,"phases":331,"primaryCompletion":332,"completion":332,"start":333,"enrollment":334,"conditions":335,"interventions":336},"NCT07225712","A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia",[85],"2028-03","2025-12-22",100,[15],[318],{"trials":338,"activeCount":93},[],{"trials":340,"activeCount":93},[],{"intervention":39,"totalTrials":12,"cells":342},{"EARLY_PHASE1":343,"PHASE1":345,"PHASE2":347,"PHASE3":356,"PHASE4":358,"NA":360},{"trials":344,"activeCount":93},[],{"trials":346,"activeCount":93},[],{"trials":348,"activeCount":12,"soonestReadout":38},[349],{"nctId":36,"briefTitle":37,"status":171,"phases":350,"primaryCompletion":38,"completion":351,"start":352,"enrollment":16,"conditions":353,"interventions":355},[83,84],"2041-01","2021-02-18",[354],"Multiple Myeloma (MM)",[39],{"trials":357,"activeCount":93},[],{"trials":359,"activeCount":93},[],{"trials":361,"activeCount":93},[],{"intervention":54,"totalTrials":12,"cells":363},{"EARLY_PHASE1":364,"PHASE1":366,"PHASE2":375,"PHASE3":377,"PHASE4":379,"NA":381},{"trials":365,"activeCount":93},[],{"trials":367,"activeCount":12,"soonestReadout":53},[368],{"nctId":51,"briefTitle":52,"status":171,"phases":369,"primaryCompletion":53,"completion":53,"start":370,"enrollment":371,"conditions":372,"interventions":374},[83],"2019-03-15",30,[373],"Lower-risk Myelodysplastic",[54,54,54,54,54],{"trials":376,"activeCount":93},[],{"trials":378,"activeCount":93},[],{"trials":380,"activeCount":93},[],{"trials":382,"activeCount":93},[],{"intervention":384,"totalTrials":19,"cells":385},"Tolvaptan",{"EARLY_PHASE1":386,"PHASE1":388,"PHASE2":390,"PHASE3":392,"PHASE4":426,"NA":437},{"trials":387,"activeCount":93},[],{"trials":389,"activeCount":93},[],{"trials":391,"activeCount":93},[],{"trials":393,"activeCount":93},[394,405,415],{"nctId":395,"briefTitle":396,"status":101,"phases":397,"primaryCompletion":398,"completion":398,"start":399,"enrollment":400,"conditions":401,"interventions":403},"NCT01280721","A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]",[85],"2014-08","2010-11",135,[402],"Autosomal Dominant Polycystic Kidney Disease （ADPKD)",[404],"tolvaptan",{"nctId":406,"briefTitle":407,"status":101,"phases":408,"primaryCompletion":409,"completion":409,"start":410,"enrollment":8,"conditions":411,"interventions":413},"NCT03048747","A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH",[85],"2019-03-19","2017-03-02",[412],"Syndrome of Inappropriate Antidiuretic Hormone Secretion",[414],"Tolvaptan Oral",{"nctId":416,"briefTitle":417,"status":101,"phases":418,"primaryCompletion":419,"completion":420,"start":421,"enrollment":422,"conditions":423,"interventions":425},"NCT03255226","Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload",[85],"2021-07-11","2021-07-15","2018-03-07",60,[424],"Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload",[384],{"trials":427,"activeCount":93},[428],{"nctId":429,"briefTitle":430,"status":101,"phases":431,"primaryCompletion":432,"completion":432,"start":433,"enrollment":334,"conditions":434,"interventions":436},"NCT01439009","Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients",[86],"2014-03","2011-09",[435],"Heart Failure",[384],{"trials":438,"activeCount":12,"soonestReadout":453},[439,449],{"nctId":440,"briefTitle":441,"status":101,"phases":442,"primaryCompletion":443,"completion":443,"start":444,"enrollment":445,"conditions":446,"interventions":448},"NCT02847624","Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD",[],"2022-09-20","2014-03-24",1802,[447],"Polycystic Kidney, Autosomal Dominant",[404],{"nctId":450,"briefTitle":451,"status":178,"phases":452,"primaryCompletion":453,"completion":454,"start":455,"enrollment":456,"conditions":457,"interventions":459},"NCT04790175","Samsca Post-marketing General Drug Use-results Survey in Patients with Hyponatremia in SIADH",[],"2028-08","2030-01","2021-03-29",300,[458],"Antidiuretic Hormone, Inappropriate Secretion",[384],{"intervention":461,"totalTrials":26,"cells":462},"Brexpiprazole",{"EARLY_PHASE1":463,"PHASE1":465,"PHASE2":467,"PHASE3":469,"PHASE4":512,"NA":514},{"trials":464,"activeCount":93},[],{"trials":466,"activeCount":93},[],{"trials":468,"activeCount":93},[],{"trials":470,"activeCount":93},[471,482,492,502],{"nctId":472,"briefTitle":473,"status":101,"phases":474,"primaryCompletion":475,"completion":476,"start":477,"enrollment":478,"conditions":479,"interventions":481},"NCT03620981","Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type",[84,85],"2023-04-21","2023-05-15","2018-08-20",410,[480],"Agitation Associated With Dementia of the Alzheimer's Type",[461],{"nctId":483,"briefTitle":484,"status":101,"phases":485,"primaryCompletion":486,"completion":487,"start":488,"enrollment":489,"conditions":490,"interventions":491},"NCT03737474","A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder",[85],"2021-03-17","2021-04-13","2018-10-04",248,[21],[461],{"nctId":493,"briefTitle":494,"status":101,"phases":495,"primaryCompletion":496,"completion":497,"start":498,"enrollment":499,"conditions":500,"interventions":501},"NCT03697603","A Study of Brexpiprazole in Patients With Major Depressive Disorder",[84,85],"2022-06-06","2022-07-04","2018-07-30",740,[21],[461],{"nctId":503,"briefTitle":504,"status":101,"phases":505,"primaryCompletion":506,"completion":507,"start":508,"enrollment":509,"conditions":510,"interventions":511},"NCT03724942","Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type",[85],"2021-12-02","2022-01-05","2018-11-09",164,[480],[461],{"trials":513,"activeCount":93},[],{"trials":515,"activeCount":12,"soonestReadout":520},[516],{"nctId":517,"briefTitle":518,"status":178,"phases":519,"primaryCompletion":520,"completion":521,"start":522,"enrollment":114,"conditions":523,"interventions":525},"NCT06875986","REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically\u002FVerbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and\u002For Outbursts Associated With Dementia Due to Alzheimer's Disease)",[],"2027-09-30","2028-09-23","2025-04-17",[524],"Alzheimer Disease",[461],{"intervention":63,"totalTrials":12,"cells":527},{"EARLY_PHASE1":528,"PHASE1":530,"PHASE2":532,"PHASE3":534,"PHASE4":536,"NA":538},{"trials":529,"activeCount":93},[],{"trials":531,"activeCount":93},[],{"trials":533,"activeCount":93},[],{"trials":535,"activeCount":93},[],{"trials":537,"activeCount":93},[],{"trials":539,"activeCount":12,"soonestReadout":62},[540],{"nctId":60,"briefTitle":61,"status":178,"phases":541,"primaryCompletion":62,"completion":542,"start":543,"enrollment":544,"conditions":545,"interventions":547},[],"2029-06-22","2022-04-20",1000,[546],"Migraine Disorders",[63],{"intervention":49,"totalTrials":12,"cells":549},{"EARLY_PHASE1":550,"PHASE1":552,"PHASE2":554,"PHASE3":556,"PHASE4":558,"NA":560},{"trials":551,"activeCount":93},[],{"trials":553,"activeCount":93},[],{"trials":555,"activeCount":93},[],{"trials":557,"activeCount":93},[],{"trials":559,"activeCount":93},[],{"trials":561,"activeCount":12,"soonestReadout":48},[562],{"nctId":46,"briefTitle":47,"status":178,"phases":563,"primaryCompletion":48,"completion":564,"start":565,"enrollment":566,"conditions":567,"interventions":568},[],"2026-05-31","2023-03-03",1600,[435],[49],{"intervention":570,"totalTrials":12,"cells":571},"Voclosporin",{"EARLY_PHASE1":572,"PHASE1":574,"PHASE2":576,"PHASE3":578,"PHASE4":580,"NA":582},{"trials":573,"activeCount":93},[],{"trials":575,"activeCount":93},[],{"trials":577,"activeCount":93},[],{"trials":579,"activeCount":93},[],{"trials":581,"activeCount":93},[],{"trials":583,"activeCount":12,"soonestReadout":588},[584],{"nctId":585,"briefTitle":586,"status":178,"phases":587,"primaryCompletion":588,"completion":589,"start":590,"enrollment":591,"conditions":592,"interventions":594},"NCT07053891","LUPKYNIS Drug-use Results Survey",[],"2031-06-30","2032-06-30","2025-09-17",400,[593],"Lupus Nephritis",[570],{"intervention":596,"totalTrials":597,"cells":598},"Aripiprazole",9,{"EARLY_PHASE1":599,"PHASE1":601,"PHASE2":603,"PHASE3":605,"PHASE4":670,"NA":681},{"trials":600,"activeCount":93},[],{"trials":602,"activeCount":93},[],{"trials":604,"activeCount":93},[],{"trials":606,"activeCount":93},[607,614,621,631,638,647,653,662],{"nctId":608,"briefTitle":609,"status":101,"phases":610,"primaryCompletion":399,"completion":399,"start":611,"enrollment":163,"conditions":612,"interventions":613},"NCT00606320","A Multicenter, Investigative Study of the Safety and Efficacy of Extended Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode",[85],"2008-01",[30],[596],{"nctId":615,"briefTitle":616,"status":101,"phases":617,"primaryCompletion":399,"completion":399,"start":611,"enrollment":618,"conditions":619,"interventions":620},"NCT00606177","A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode",[85],99,[30],[596],{"nctId":622,"briefTitle":623,"status":101,"phases":624,"primaryCompletion":625,"completion":625,"start":626,"enrollment":627,"conditions":628,"interventions":630},"NCT01617460","A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder",[85],"2016-10","2012-09",86,[629],"Autistic Disorder",[596],{"nctId":632,"briefTitle":633,"status":101,"phases":634,"primaryCompletion":399,"completion":399,"start":611,"enrollment":635,"conditions":636,"interventions":637},"NCT00606281","A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode",[85],258,[30],[596],{"nctId":639,"briefTitle":640,"status":101,"phases":641,"primaryCompletion":642,"completion":642,"start":643,"enrollment":644,"conditions":645,"interventions":646},"NCT01942148","A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia",[85],"2015-11","2010-08",68,[15],[596],{"nctId":648,"briefTitle":649,"status":101,"phases":650,"primaryCompletion":399,"completion":399,"start":611,"enrollment":135,"conditions":651,"interventions":652},"NCT00606229","A Multicenter Investigative Study of the Safety and Efficacy of Long-term Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode",[85],[30],[596],{"nctId":654,"briefTitle":655,"status":101,"phases":656,"primaryCompletion":657,"completion":657,"start":658,"enrollment":659,"conditions":660,"interventions":661},"NCT01617447","A Short Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder",[85],"2015-06","2012-07",92,[629],[596],{"nctId":663,"briefTitle":664,"status":101,"phases":665,"primaryCompletion":658,"completion":658,"start":666,"enrollment":667,"conditions":668,"interventions":669},"NCT00876343","Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder",[85],"2009-03",586,[21],[596,596],{"trials":671,"activeCount":93},[672],{"nctId":673,"briefTitle":674,"status":101,"phases":675,"primaryCompletion":676,"completion":676,"start":677,"enrollment":678,"conditions":679,"interventions":680},"NCT00392197","Study of Aripiprazole in Patients With Schizophrenia- Effects on Glucose Metabolism-",[86],"2010-03","2006-11",111,[15],[596],{"trials":682,"activeCount":93},[],{"intervention":684,"totalTrials":150,"cells":685},"Rebamipide",{"EARLY_PHASE1":686,"PHASE1":688,"PHASE2":690,"PHASE3":715,"PHASE4":717,"NA":730},{"trials":687,"activeCount":93},[],{"trials":689,"activeCount":93},[],{"trials":691,"activeCount":93},[692,703],{"nctId":693,"briefTitle":694,"status":101,"phases":695,"primaryCompletion":696,"completion":696,"start":697,"enrollment":698,"conditions":699,"interventions":701},"NCT00463151","An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis",[84],"2008-08","2007-06",124,[700],"Colitis, Ulcerative",[702],"rebamipide",{"nctId":704,"briefTitle":705,"status":101,"phases":706,"primaryCompletion":707,"completion":708,"start":709,"enrollment":710,"conditions":711,"interventions":714},"NCT00233363","Exploratory Study for Dry Mouth in Patients With Sjögren's Syndrome",[84],"2006-01-19","2006-01-27","2005-04-15",104,[712,713],"Xerostomia","Sjogren's Syndrome",[684],{"trials":716,"activeCount":93},[],{"trials":718,"activeCount":93},[719],{"nctId":720,"briefTitle":721,"status":101,"phases":722,"primaryCompletion":723,"completion":724,"start":725,"enrollment":726,"conditions":727,"interventions":729},"NCT00233389","Post-marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer",[86],"2005-09-01","2005-09-09","2004-04-30",301,[728],"Stomach Ulcer",[684],{"trials":731,"activeCount":93},[],{"intervention":733,"totalTrials":150,"cells":734},"Cilostazol",{"EARLY_PHASE1":735,"PHASE1":737,"PHASE2":751,"PHASE3":753,"PHASE4":766,"NA":778},{"trials":736,"activeCount":93},[],{"trials":738,"activeCount":93},[739],{"nctId":740,"briefTitle":741,"status":101,"phases":742,"primaryCompletion":743,"completion":743,"start":744,"enrollment":745,"conditions":746,"interventions":748},"NCT02554721","Pharmacodynamic Study of Cilostazol in Healthy Volunteers",[83],"2018-03-30","2015-08",77,[747],"Healthy",[733,749,750],"Acetylsalicylic acid","Clopidogrel",{"trials":752,"activeCount":93},[],{"trials":754,"activeCount":93},[755],{"nctId":756,"briefTitle":757,"status":101,"phases":758,"primaryCompletion":759,"completion":759,"start":760,"enrollment":761,"conditions":762,"interventions":764},"NCT00766545","Cilostazol Stroke Prevention Study : A Placebo-controlled Double-blind Trial for Secondary Prevention of Cerebral Infarction.",[85],"1997-03","1992-04",1095,[763],"Cerebral Infarction",[765],"cilostazol",{"trials":767,"activeCount":93},[768],{"nctId":769,"briefTitle":770,"status":101,"phases":771,"primaryCompletion":772,"completion":772,"start":773,"enrollment":774,"conditions":775,"interventions":776},"NCT00234065","Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)",[86],"2008-12","2003-12",2800,[763],[733,777],"Aspirin",{"trials":779,"activeCount":93},[],{"intervention":777,"totalTrials":12,"cells":781},{"EARLY_PHASE1":782,"PHASE1":784,"PHASE2":786,"PHASE3":788,"PHASE4":790,"NA":796},{"trials":783,"activeCount":93},[],{"trials":785,"activeCount":93},[],{"trials":787,"activeCount":93},[],{"trials":789,"activeCount":93},[],{"trials":791,"activeCount":93},[792],{"nctId":769,"briefTitle":770,"status":101,"phases":793,"primaryCompletion":772,"completion":772,"start":773,"enrollment":774,"conditions":794,"interventions":795},[86],[763],[733,777],{"trials":797,"activeCount":93},[],{"intervention":799,"totalTrials":800,"cells":801},"OPC-41061",13,{"EARLY_PHASE1":802,"PHASE1":804,"PHASE2":816,"PHASE3":874,"PHASE4":931,"NA":933},{"trials":803,"activeCount":93},[],{"trials":805,"activeCount":93},[806],{"nctId":807,"briefTitle":808,"status":101,"phases":809,"primaryCompletion":810,"completion":810,"start":811,"enrollment":812,"conditions":813,"interventions":815},"NCT02994394","A Study of OPC-41061 Orally Disintegrating (OD) Tablets Using 2 Different Formulations and 2 Dosing Regimens in Healthy Adult Male Subjects",[83],"2017-02-28","2017-01-06",84,[814],"Healthy Adult Male",[799],{"trials":817,"activeCount":93},[818,827,838,847,856,864],{"nctId":819,"briefTitle":820,"status":101,"phases":821,"primaryCompletion":822,"completion":822,"start":823,"enrollment":698,"conditions":824,"interventions":826},"NCT02331680","A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration",[84],"2016-05","2014-12",[825],"Chronic Renal Failure",[799,799],{"nctId":828,"briefTitle":829,"status":101,"phases":830,"primaryCompletion":831,"completion":831,"start":832,"enrollment":833,"conditions":834,"interventions":837},"NCT00234104","A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure)",[84],"2006-01","2004-08",122,[835,836],"Heart Failure, Congestive","Edema",[799],{"nctId":839,"briefTitle":840,"status":101,"phases":841,"primaryCompletion":842,"completion":398,"start":843,"enrollment":844,"conditions":845,"interventions":846},"NCT01895322","Open-label Dose-finding Trial of OPC-41061 in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis",[84],"2014-02","2013-07",20,[825],[799],{"nctId":848,"briefTitle":849,"status":101,"phases":850,"primaryCompletion":399,"completion":399,"start":851,"enrollment":852,"conditions":853,"interventions":855},"NCT00841568","A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]",[84],"2006-04",17,[854],"Autosomal Dominant Polycystic Kidney Disease",[799],{"nctId":857,"briefTitle":858,"status":101,"phases":859,"primaryCompletion":842,"completion":842,"start":860,"enrollment":861,"conditions":862,"interventions":863},"NCT01876381","A Phase 2, Multi-center, Open-label, Dose-finding Trial to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of OPC-41061 in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration",[84],"2013-06",26,[825],[799],{"nctId":865,"briefTitle":866,"status":101,"phases":867,"primaryCompletion":868,"completion":869,"start":658,"enrollment":870,"conditions":871,"interventions":873},"NCT01684202","A Multicenter, Open-label, Dose-finding Trial of OPC-41061 to Investigate Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety in Patients With Carcinomatous Edema (Phase 2)",[84],"2013-12","2014-06",43,[872],"Carcinomatous Edema",[799],{"trials":875,"activeCount":93},[876,884,893,903,913,921],{"nctId":877,"briefTitle":878,"status":101,"phases":879,"primaryCompletion":880,"completion":880,"start":881,"enrollment":800,"conditions":882,"interventions":883},"NCT01022424","A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]",[85],"2014-07","2009-11",[854],[799],{"nctId":885,"briefTitle":886,"status":101,"phases":887,"primaryCompletion":888,"completion":888,"start":889,"enrollment":844,"conditions":890,"interventions":892},"NCT00525265","A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)",[85],"2009-01","2007-09",[891],"Cardiac Edema",[799],{"nctId":894,"briefTitle":895,"status":101,"phases":896,"primaryCompletion":897,"completion":897,"start":898,"enrollment":899,"conditions":900,"interventions":902},"NCT01050530","A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema",[85],"2012-02","2009-12",162,[901],"Cirrhosis",[799],{"nctId":904,"briefTitle":905,"status":101,"phases":906,"primaryCompletion":907,"completion":908,"start":909,"enrollment":910,"conditions":911,"interventions":912},"NCT01114828","A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema",[85],"2011-10","2011-12","2010-02",40,[901],[799,799],{"nctId":914,"briefTitle":915,"status":101,"phases":916,"primaryCompletion":917,"completion":917,"start":898,"enrollment":918,"conditions":919,"interventions":920},"NCT01048788","A Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mg",[85],"2011-08",51,[901],[799],{"nctId":922,"briefTitle":923,"status":101,"phases":924,"primaryCompletion":925,"completion":925,"start":926,"enrollment":927,"conditions":928,"interventions":930},"NCT00462670","A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)",[85],"2008-10","2007-04",110,[929],"Edema, Cardiac",[799],{"trials":932,"activeCount":93},[],{"trials":934,"activeCount":93},[],{"intervention":936,"totalTrials":937,"cells":938},"SPM 962",10,{"EARLY_PHASE1":939,"PHASE1":941,"PHASE2":943,"PHASE3":989,"PHASE4":1030,"NA":1032},{"trials":940,"activeCount":93},[],{"trials":942,"activeCount":93},[],{"trials":944,"activeCount":93},[945,954,962,972,980],{"nctId":946,"briefTitle":947,"status":101,"phases":948,"primaryCompletion":949,"completion":949,"start":950,"enrollment":951,"conditions":952,"interventions":953},"NCT01628848","A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients",[84],"2008-04","2006-08",174,[18],[936],{"nctId":955,"briefTitle":956,"status":101,"phases":957,"primaryCompletion":909,"completion":909,"start":958,"enrollment":959,"conditions":960,"interventions":961},"NCT01631812","A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease Patients",[84],"2006-12",130,[18],[936],{"nctId":963,"briefTitle":964,"status":101,"phases":965,"primaryCompletion":966,"completion":966,"start":967,"enrollment":968,"conditions":969,"interventions":971},"NCT00666965","A Placebo-Controlled Study for SPM 962 in Restless Legs Syndrome (RLS) Patients",[84],"2009-08","2008-06",230,[970],"Idiopathic Restless Legs Syndrome",[936],{"nctId":973,"briefTitle":974,"status":101,"phases":975,"primaryCompletion":976,"completion":976,"start":696,"enrollment":977,"conditions":978,"interventions":979},"NCT01562743","A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs Syndrome",[84],"2010-10",185,[970],[936],{"nctId":981,"briefTitle":982,"status":101,"phases":983,"primaryCompletion":984,"completion":984,"start":985,"enrollment":986,"conditions":987,"interventions":988},"NCT01634243","A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients",[84],"2006-05","2005-01",64,[18],[936],{"trials":990,"activeCount":93},[991,1000,1007,1013,1020],{"nctId":992,"briefTitle":993,"status":101,"phases":994,"primaryCompletion":995,"completion":995,"start":996,"enrollment":997,"conditions":998,"interventions":999},"NCT01631825","A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients",[85],"2012-06","2009-10",321,[18],[936],{"nctId":1001,"briefTitle":1002,"status":101,"phases":1003,"primaryCompletion":433,"completion":433,"start":909,"enrollment":1004,"conditions":1005,"interventions":1006},"NCT01084551","Study of SPM 962 in Patients With Restless Legs Syndrome (RLS)",[85],284,[970],[936,936],{"nctId":1008,"briefTitle":1009,"status":101,"phases":1010,"primaryCompletion":976,"completion":976,"start":611,"enrollment":6,"conditions":1011,"interventions":1012},"NCT01628965","A Long-Term Extension Trial From Phase II\u002FIII of SPM 962 in Early Parkinson's Disease Patients",[84,85],[18],[936],{"nctId":1014,"briefTitle":1015,"status":101,"phases":1016,"primaryCompletion":898,"completion":898,"start":889,"enrollment":211,"conditions":1017,"interventions":1019},"NCT00537485","A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients",[84,85],[1018],"Early Parkinson's Disease",[936],{"nctId":1021,"briefTitle":1022,"status":101,"phases":1023,"primaryCompletion":1024,"completion":1024,"start":1025,"enrollment":1026,"conditions":1027,"interventions":1028},"NCT01628926","A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients",[85],"2011-05","2009-06",420,[18],[936,1029],"Ropinirole",{"trials":1031,"activeCount":93},[],{"trials":1033,"activeCount":93},[],{"intervention":1035,"totalTrials":31,"cells":1036},"OPC-12759 Ophthalmic suspension",{"EARLY_PHASE1":1037,"PHASE1":1039,"PHASE2":1049,"PHASE3":1063,"PHASE4":1084,"NA":1086},{"trials":1038,"activeCount":93},[],{"trials":1040,"activeCount":93},[1041],{"nctId":1042,"briefTitle":1043,"status":101,"phases":1044,"primaryCompletion":908,"completion":897,"start":1045,"enrollment":334,"conditions":1046,"interventions":1047},"NCT01471093","Safety Study of OPC-12759 Ophthalmic Solution",[83],"2011-11",[28],[1048,1035],"OPC-12759 Ophthalmic solution",{"trials":1050,"activeCount":93},[1051],{"nctId":1052,"briefTitle":1053,"status":101,"phases":1054,"primaryCompletion":1055,"completion":1056,"start":908,"enrollment":1057,"conditions":1058,"interventions":1060},"NCT01493180","Exploratory Study of OPC-12759 Ophthalmic Suspension",[84],"2012-11","2012-12",102,[1059],"Keratoconjunctival Epithelial Disorder",[1061,1062],"OPC-12759 ophthalmic suspension","Sodium hyaluronate ophthalmic solution",{"trials":1064,"activeCount":93},[1065,1074],{"nctId":1066,"briefTitle":1067,"status":101,"phases":1068,"primaryCompletion":1069,"completion":1070,"start":888,"enrollment":1071,"conditions":1072,"interventions":1073},"NCT00818324","Long Term Administration Study of OPC-12759 Ophthalmic Suspension",[85],"2010-09","2011-01",154,[28],[1035],{"nctId":1075,"briefTitle":1076,"status":101,"phases":1077,"primaryCompletion":676,"completion":1078,"start":1079,"enrollment":1080,"conditions":1081,"interventions":1082},"NCT00885079","Confirmatory Study of OPC-12759 Ophthalmic Suspension",[85],"2010-04","2009-05",188,[28],[1035,1083],"Hyalein Mini Ophthalmic solution",{"trials":1085,"activeCount":93},[],{"trials":1087,"activeCount":93},[],{"intervention":108,"totalTrials":31,"cells":1089},{"EARLY_PHASE1":1090,"PHASE1":1092,"PHASE2":1107,"PHASE3":1113,"PHASE4":1135,"NA":1137},{"trials":1091,"activeCount":93},[],{"trials":1093,"activeCount":93},[1094],{"nctId":1095,"briefTitle":1096,"status":101,"phases":1097,"primaryCompletion":1098,"completion":1098,"start":1099,"enrollment":1100,"conditions":1101,"interventions":1103},"NCT03510663","Phase I Study of OPC-61815",[83],"2018-07-05","2018-05-08",48,[1102],"Congestive Heart Failure",[1104,1105,1106,108],"OPC-61815 16mg","OPC-61815 32mg","Moxifloxacin",{"trials":1108,"activeCount":93},[1109],{"nctId":99,"briefTitle":100,"status":101,"phases":1110,"primaryCompletion":103,"completion":103,"start":104,"enrollment":105,"conditions":1111,"interventions":1112},[84],[23],[68,108],{"trials":1114,"activeCount":93},[1115,1126],{"nctId":1116,"briefTitle":1117,"status":101,"phases":1118,"primaryCompletion":1119,"completion":1119,"start":1120,"enrollment":1121,"conditions":1122,"interventions":1123},"NCT03911401","Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis",[85],"2019-12-13","2019-05-07",251,[23],[1124,1125,108],"0.3% OPA-15406","1% OPA-15406",{"nctId":1127,"briefTitle":1128,"status":101,"phases":1129,"primaryCompletion":1130,"completion":1130,"start":1131,"enrollment":1132,"conditions":1133,"interventions":1134},"NCT03908970","Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndrome",[85],"2019-12-28","2019-03-25",364,[23],[1125,108],{"trials":1136,"activeCount":93},[],{"trials":1138,"activeCount":93},[],{"intervention":1140,"totalTrials":150,"cells":1141},"180mg of ETC-1002",{"EARLY_PHASE1":1142,"PHASE1":1144,"PHASE2":1146,"PHASE3":1160,"PHASE4":1182,"NA":1184},{"trials":1143,"activeCount":93},[],{"trials":1145,"activeCount":93},[],{"trials":1147,"activeCount":93},[1148],{"nctId":1149,"briefTitle":1150,"status":101,"phases":1151,"primaryCompletion":1152,"completion":1153,"start":1154,"enrollment":1080,"conditions":1155,"interventions":1157},"NCT04784442","A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia",[84],"2022-04-18","2022-05-17","2021-03-24",[1156],"Hypercholesterolemia",[1140,1158,1159],"120mg of ETC-1002","60mg of ETC-1002",{"trials":1161,"activeCount":93},[1162,1172],{"nctId":1163,"briefTitle":1164,"status":101,"phases":1165,"primaryCompletion":1166,"completion":1167,"start":1168,"enrollment":959,"conditions":1169,"interventions":1171},"NCT05687071","A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia",[85],"2024-10-05","2024-11-02","2023-02-27",[1170],"Hyper-low-density Lipoprotein (LDL) Cholesterolemia",[1140],{"nctId":1173,"briefTitle":1174,"status":101,"phases":1175,"primaryCompletion":1176,"completion":1177,"start":1178,"enrollment":1179,"conditions":1180,"interventions":1181},"NCT05683340","A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia",[85],"2024-02-20","2024-03-12","2023-02-13",96,[1170],[1140],{"trials":1183,"activeCount":93},[],{"trials":1185,"activeCount":93},[],{"intervention":1187,"totalTrials":150,"cells":1188},"TEV-48125",{"EARLY_PHASE1":1189,"PHASE1":1191,"PHASE2":1193,"PHASE3":1195,"PHASE4":1224,"NA":1226},{"trials":1190,"activeCount":93},[],{"trials":1192,"activeCount":93},[],{"trials":1194,"activeCount":93},[],{"trials":1196,"activeCount":93},[1197,1206,1216],{"nctId":1198,"briefTitle":1199,"status":101,"phases":1200,"primaryCompletion":1201,"completion":1201,"start":1202,"enrollment":1203,"conditions":1204,"interventions":1205},"NCT03303105","Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine",[85],"2020-06-16","2017-12-07",50,[33],[1187,1187],{"nctId":1207,"briefTitle":1208,"status":101,"phases":1209,"primaryCompletion":1210,"completion":1210,"start":1211,"enrollment":1212,"conditions":1213,"interventions":1214},"NCT03303079","Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine",[84,85],"2019-11-30","2017-12-19",571,[33],[1187,1215],"TEV-48125 or placebo",{"nctId":1217,"briefTitle":1218,"status":101,"phases":1219,"primaryCompletion":1220,"completion":1220,"start":1211,"enrollment":1221,"conditions":1222,"interventions":1223},"NCT03303092","Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine",[84,85],"2019-11-22",357,[33],[1187,1215],{"trials":1225,"activeCount":93},[],{"trials":1227,"activeCount":93},[],{"intervention":1229,"totalTrials":150,"cells":1230},"OPC-6535",{"EARLY_PHASE1":1231,"PHASE1":1233,"PHASE2":1235,"PHASE3":1254,"PHASE4":1265,"NA":1267},{"trials":1232,"activeCount":93},[],{"trials":1234,"activeCount":93},[],{"trials":1236,"activeCount":93},[1237,1248],{"nctId":1238,"briefTitle":1239,"status":1240,"phases":1241,"primaryCompletion":1242,"completion":1243,"start":984,"enrollment":1244,"conditions":1245,"interventions":1247},"NCT00317369","A Dose-finding Study of OPC-6535 in Patients With Active Crohn's Disease","TERMINATED",[84],"2007-07-11","2007-08",29,[1246],"Crohn Disease",[1229],{"nctId":1249,"briefTitle":1250,"status":1240,"phases":1251,"primaryCompletion":1243,"completion":1243,"start":984,"enrollment":870,"conditions":1252,"interventions":1253},"NCT00317356","A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis",[84],[700],[1229],{"trials":1255,"activeCount":93},[1256],{"nctId":1257,"briefTitle":1258,"status":101,"phases":1259,"primaryCompletion":1260,"completion":1260,"start":996,"enrollment":1261,"conditions":1262,"interventions":1264},"NCT00989573","A Dose-finding and Confirmatory Trial of OPC-6535 in Patients With Active Crohn's Disease",[84,85],"2012-08",191,[1263],"Crohn's Disease",[1229,1229],{"trials":1266,"activeCount":93},[],{"trials":1268,"activeCount":93},[],{"intervention":1270,"totalTrials":150,"cells":1271},"OPC-1085EL ophthalmic solution",{"EARLY_PHASE1":1272,"PHASE1":1274,"PHASE2":1288,"PHASE3":1290,"PHASE4":1307,"NA":1309},{"trials":1273,"activeCount":93},[],{"trials":1275,"activeCount":93},[1276],{"nctId":1277,"briefTitle":1278,"status":101,"phases":1279,"primaryCompletion":1280,"completion":398,"start":1281,"enrollment":371,"conditions":1282,"interventions":1285},"NCT02108288","Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers",[83],"2014-05","2014-04",[1283,1284],"Glaucoma","Ocular Hypertension",[1270,1286,1287],"Carteolol long-acting ophthalmic solution","Latanoprost ophthalmic solution",{"trials":1289,"activeCount":93},[],{"trials":1291,"activeCount":93},[1292,1300],{"nctId":1293,"briefTitle":1294,"status":101,"phases":1295,"primaryCompletion":1296,"completion":1296,"start":1281,"enrollment":1297,"conditions":1298,"interventions":1299},"NCT02105272","Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension",[85],"2015-03",237,[1283,1284],[1270,1287],{"nctId":1301,"briefTitle":1294,"status":101,"phases":1302,"primaryCompletion":1303,"completion":1303,"start":1281,"enrollment":1304,"conditions":1305,"interventions":1306},"NCT02105285",[85],"2015-01",193,[1283,1284],[1270,1286],{"trials":1308,"activeCount":93},[],{"trials":1310,"activeCount":93},[],{"intervention":1312,"totalTrials":150,"cells":1313},"ASC-01",{"EARLY_PHASE1":1314,"PHASE1":1316,"PHASE2":1337,"PHASE3":1339,"PHASE4":1348,"NA":1350},{"trials":1315,"activeCount":93},[],{"trials":1317,"activeCount":93},[1318,1329],{"nctId":1319,"briefTitle":1320,"status":101,"phases":1321,"primaryCompletion":1322,"completion":1322,"start":1323,"enrollment":1324,"conditions":1325,"interventions":1327},"NCT03342963","Bioequivalence Between Single Administration of ASC-01 (Aripiprazole\u002FSertraline Combination Drug) and Concomitant Single Administration of Aripiprazole and Sertraline, and Food Effect on Pharmacokinetics of ASC-01 in Healthy Male Adults",[83],"2018-01-18","2017-11-21",74,[1326],"Healthy Male Adults",[1312,1328],"Aripiprazole and sertraline",{"nctId":1330,"briefTitle":1331,"status":101,"phases":1332,"primaryCompletion":1333,"completion":1333,"start":868,"enrollment":1203,"conditions":1334,"interventions":1336},"NCT02088697","A Bioequivalence Study of ASC-01 Placebo (Aripiprazole 0 mg\u002FSertraline 100 mg) and Sertraline Tablet in Healthy Male Subjects",[83],"2014-01",[1335],"Healthy Volunteers",[1312],{"trials":1338,"activeCount":93},[],{"trials":1340,"activeCount":93},[1341],{"nctId":1342,"briefTitle":1343,"status":101,"phases":1344,"primaryCompletion":113,"completion":113,"start":842,"enrollment":1345,"conditions":1346,"interventions":1347},"NCT02046564","Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder",[85],412,[21],[1312],{"trials":1349,"activeCount":93},[],{"trials":1351,"activeCount":93},[],{"intervention":1353,"totalTrials":150,"cells":1354},"OPC-34712",{"EARLY_PHASE1":1355,"PHASE1":1357,"PHASE2":1368,"PHASE3":1370,"PHASE4":1387,"NA":1389},{"trials":1356,"activeCount":93},[],{"trials":1358,"activeCount":93},[1359],{"nctId":1360,"briefTitle":1361,"status":101,"phases":1362,"primaryCompletion":1363,"completion":1363,"start":1364,"enrollment":1365,"conditions":1366,"interventions":1367},"NCT02875080","Evaluation Study of the Bioavailability of Brexpiprazole Orally Disintegrating Tablets in Healthy Male Subjects",[83],"2016-11-27","2016-09-27",18,[814],[1353],{"trials":1369,"activeCount":93},[],{"trials":1371,"activeCount":93},[1372,1380],{"nctId":1373,"briefTitle":1374,"status":101,"phases":1375,"primaryCompletion":1376,"start":907,"enrollment":1377,"conditions":1378,"interventions":1379},"NCT01456897","A Long-term Trial of OPC-34712 in Patients With Schizophrenia",[85],"2015-05",282,[15],[1353],{"nctId":1381,"briefTitle":1382,"status":101,"phases":1383,"primaryCompletion":657,"start":907,"enrollment":1384,"conditions":1385,"interventions":1386},"NCT01451164","A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia",[84,85],459,[15],[1353,1353,1353],{"trials":1388,"activeCount":93},[],{"trials":1390,"activeCount":93},[],{"intervention":1287,"totalTrials":144,"cells":1392},{"EARLY_PHASE1":1393,"PHASE1":1395,"PHASE2":1401,"PHASE3":1403,"PHASE4":1409,"NA":1411},{"trials":1394,"activeCount":93},[],{"trials":1396,"activeCount":93},[1397],{"nctId":1277,"briefTitle":1278,"status":101,"phases":1398,"primaryCompletion":1280,"completion":398,"start":1281,"enrollment":371,"conditions":1399,"interventions":1400},[83],[1283,1284],[1270,1286,1287],{"trials":1402,"activeCount":93},[],{"trials":1404,"activeCount":93},[1405],{"nctId":1293,"briefTitle":1294,"status":101,"phases":1406,"primaryCompletion":1296,"completion":1296,"start":1281,"enrollment":1297,"conditions":1407,"interventions":1408},[85],[1283,1284],[1270,1287],{"trials":1410,"activeCount":93},[],{"trials":1412,"activeCount":93},[],{"intervention":1414,"totalTrials":144,"cells":1415},"0.3% OPA-15406 ointment",{"EARLY_PHASE1":1416,"PHASE1":1418,"PHASE2":1431,"PHASE3":1433,"PHASE4":1445,"NA":1447},{"trials":1417,"activeCount":93},[],{"trials":1419,"activeCount":93},[1420],{"nctId":1421,"briefTitle":1422,"status":101,"phases":1423,"primaryCompletion":1424,"completion":1424,"start":1303,"enrollment":1425,"conditions":1426,"interventions":1427},"NCT02334787","A Phase 1 Trial of OPA-15406 Ointment in Healthy Adult Male Subjects",[83],"2015-02",32,[23],[1428,1429,1430],"0.3% OPA-15406 Ointment","1% OPA-15406 Ointment","3% OPA-15406 Ointment",{"trials":1432,"activeCount":93},[],{"trials":1434,"activeCount":93},[1435],{"nctId":1436,"briefTitle":1437,"status":101,"phases":1438,"primaryCompletion":1439,"completion":1439,"start":1440,"enrollment":1441,"conditions":1442,"interventions":1443},"NCT03961529","Long-term Trial of OPA-15406 Ointment in Adult and Pediatric Patients With Atopic Dermatitis",[85],"2020-11-11","2019-05-14",366,[23],[1414,1444],"1% OPA-15406 ointment",{"trials":1446,"activeCount":93},[],{"trials":1448,"activeCount":93},[],{"intervention":1444,"totalTrials":144,"cells":1450},{"EARLY_PHASE1":1451,"PHASE1":1453,"PHASE2":1459,"PHASE3":1461,"PHASE4":1467,"NA":1469},{"trials":1452,"activeCount":93},[],{"trials":1454,"activeCount":93},[1455],{"nctId":1421,"briefTitle":1422,"status":101,"phases":1456,"primaryCompletion":1424,"completion":1424,"start":1303,"enrollment":1425,"conditions":1457,"interventions":1458},[83],[23],[1428,1429,1430],{"trials":1460,"activeCount":93},[],{"trials":1462,"activeCount":93},[1463],{"nctId":1436,"briefTitle":1437,"status":101,"phases":1464,"primaryCompletion":1439,"completion":1439,"start":1440,"enrollment":1441,"conditions":1465,"interventions":1466},[85],[23],[1414,1444],{"trials":1468,"activeCount":93},[],{"trials":1470,"activeCount":93},[],{"intervention":1472,"totalTrials":144,"cells":1473},"Nalmefene hydrochloride",{"EARLY_PHASE1":1474,"PHASE1":1476,"PHASE2":1478,"PHASE3":1480,"PHASE4":1501,"NA":1503},{"trials":1475,"activeCount":93},[],{"trials":1477,"activeCount":93},[],{"trials":1479,"activeCount":93},[],{"trials":1481,"activeCount":93},[1482,1492],{"nctId":1483,"briefTitle":1484,"status":101,"phases":1485,"primaryCompletion":1486,"completion":1486,"start":1487,"enrollment":1488,"conditions":1489,"interventions":1491},"NCT02382276","A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence",[85],"2017-01-18","2015-07-13",405,[1490],"Alcohol Dependence",[1472],{"nctId":1493,"briefTitle":1494,"status":101,"phases":1495,"primaryCompletion":1496,"completion":1496,"start":1497,"enrollment":1498,"conditions":1499,"interventions":1500},"NCT02364947","A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial)",[85],"2016-07-30","2015-02-09",678,[1490],[1472],{"trials":1502,"activeCount":93},[],{"trials":1504,"activeCount":93},[],{"intervention":1506,"totalTrials":144,"cells":1507},"OPC-61815",{"EARLY_PHASE1":1508,"PHASE1":1510,"PHASE2":1512,"PHASE3":1514,"PHASE4":1536,"NA":1538},{"trials":1509,"activeCount":93},[],{"trials":1511,"activeCount":93},[],{"trials":1513,"activeCount":93},[],{"trials":1515,"activeCount":93},[1516,1527],{"nctId":1517,"briefTitle":1518,"status":101,"phases":1519,"primaryCompletion":1520,"completion":1521,"start":1522,"enrollment":1523,"conditions":1524,"interventions":1525},"NCT03772041","Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure",[85],"2020-07-21","2020-07-29","2019-01-16",294,[1102],[1506,1526],"Tolvaptan Tab 15 MG",{"nctId":1528,"briefTitle":1529,"status":101,"phases":1530,"primaryCompletion":1531,"completion":1531,"start":1532,"enrollment":1533,"conditions":1534,"interventions":1535},"NCT03962101","Safety Trial of OPC-61815 Injection in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral Intake",[85],"2020-06-30","2019-06-17",45,[1102],[1506],{"trials":1537,"activeCount":93},[],{"trials":1539,"activeCount":93},[],{"intervention":1215,"totalTrials":144,"cells":1541},{"EARLY_PHASE1":1542,"PHASE1":1544,"PHASE2":1546,"PHASE3":1548,"PHASE4":1558,"NA":1560},{"trials":1543,"activeCount":93},[],{"trials":1545,"activeCount":93},[],{"trials":1547,"activeCount":93},[],{"trials":1549,"activeCount":93},[1550,1554],{"nctId":1207,"briefTitle":1208,"status":101,"phases":1551,"primaryCompletion":1210,"completion":1210,"start":1211,"enrollment":1212,"conditions":1552,"interventions":1553},[84,85],[33],[1187,1215],{"nctId":1217,"briefTitle":1218,"status":101,"phases":1555,"primaryCompletion":1220,"completion":1220,"start":1211,"enrollment":1221,"conditions":1556,"interventions":1557},[84,85],[33],[1187,1215],{"trials":1559,"activeCount":93},[],{"trials":1561,"activeCount":93},[],{"intervention":1125,"totalTrials":144,"cells":1563},{"EARLY_PHASE1":1564,"PHASE1":1566,"PHASE2":1568,"PHASE3":1570,"PHASE4":1580,"NA":1582},{"trials":1565,"activeCount":93},[],{"trials":1567,"activeCount":93},[],{"trials":1569,"activeCount":93},[],{"trials":1571,"activeCount":93},[1572,1576],{"nctId":1116,"briefTitle":1117,"status":101,"phases":1573,"primaryCompletion":1119,"completion":1119,"start":1120,"enrollment":1121,"conditions":1574,"interventions":1575},[85],[23],[1124,1125,108],{"nctId":1127,"briefTitle":1128,"status":101,"phases":1577,"primaryCompletion":1130,"completion":1130,"start":1131,"enrollment":1132,"conditions":1578,"interventions":1579},[85],[23],[1125,108],{"trials":1581,"activeCount":93},[],{"trials":1583,"activeCount":93},[],{"intervention":1286,"totalTrials":144,"cells":1585},{"EARLY_PHASE1":1586,"PHASE1":1588,"PHASE2":1594,"PHASE3":1596,"PHASE4":1602,"NA":1604},{"trials":1587,"activeCount":93},[],{"trials":1589,"activeCount":93},[1590],{"nctId":1277,"briefTitle":1278,"status":101,"phases":1591,"primaryCompletion":1280,"completion":398,"start":1281,"enrollment":371,"conditions":1592,"interventions":1593},[83],[1283,1284],[1270,1286,1287],{"trials":1595,"activeCount":93},[],{"trials":1597,"activeCount":93},[1598],{"nctId":1301,"briefTitle":1294,"status":101,"phases":1599,"primaryCompletion":1303,"completion":1303,"start":1281,"enrollment":1304,"conditions":1600,"interventions":1601},[85],[1283,1284],[1270,1286],{"trials":1603,"activeCount":93},[],{"trials":1605,"activeCount":93},[],{"intervention":1607,"totalTrials":12,"cells":1608},"2 mg\u002Fday",{"EARLY_PHASE1":1609,"PHASE1":1611,"PHASE2":1613,"PHASE3":1615,"PHASE4":1628,"NA":1630},{"trials":1610,"activeCount":93},[],{"trials":1612,"activeCount":93},[],{"trials":1614,"activeCount":93},[],{"trials":1616,"activeCount":93},[1617],{"nctId":1618,"briefTitle":1619,"status":1240,"phases":1620,"primaryCompletion":1621,"completion":1621,"start":1622,"enrollment":1623,"conditions":1624,"interventions":1625},"NCT02168920","Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type",[85],"2016-03-18","2014-06-11",150,[480],[1607,1626,1627],"3 mg\u002Fday","6 mg\u002Fday",{"trials":1629,"activeCount":93},[],{"trials":1631,"activeCount":93},[],{"intervention":1626,"totalTrials":12,"cells":1633},{"EARLY_PHASE1":1634,"PHASE1":1636,"PHASE2":1638,"PHASE3":1640,"PHASE4":1646,"NA":1648},{"trials":1635,"activeCount":93},[],{"trials":1637,"activeCount":93},[],{"trials":1639,"activeCount":93},[],{"trials":1641,"activeCount":93},[1642],{"nctId":1618,"briefTitle":1619,"status":1240,"phases":1643,"primaryCompletion":1621,"completion":1621,"start":1622,"enrollment":1623,"conditions":1644,"interventions":1645},[85],[480],[1607,1626,1627],{"trials":1647,"activeCount":93},[],{"trials":1649,"activeCount":93},[],{"intervention":1627,"totalTrials":12,"cells":1651},{"EARLY_PHASE1":1652,"PHASE1":1654,"PHASE2":1656,"PHASE3":1658,"PHASE4":1664,"NA":1666},{"trials":1653,"activeCount":93},[],{"trials":1655,"activeCount":93},[],{"trials":1657,"activeCount":93},[],{"trials":1659,"activeCount":93},[1660],{"nctId":1618,"briefTitle":1619,"status":1240,"phases":1661,"primaryCompletion":1621,"completion":1621,"start":1622,"enrollment":1623,"conditions":1662,"interventions":1663},[85],[480],[1607,1626,1627],{"trials":1665,"activeCount":93},[],{"trials":1667,"activeCount":93},[],{"intervention":1669,"totalTrials":12,"cells":1670},"OPC-12759",{"EARLY_PHASE1":1671,"PHASE1":1673,"PHASE2":1675,"PHASE3":1677,"PHASE4":1689,"NA":1691},{"trials":1672,"activeCount":93},[],{"trials":1674,"activeCount":93},[],{"trials":1676,"activeCount":93},[],{"trials":1678,"activeCount":93},[1679],{"nctId":1680,"briefTitle":1681,"status":101,"phases":1682,"primaryCompletion":1683,"completion":1684,"start":1260,"enrollment":1685,"conditions":1686,"interventions":1688},"NCT01660256","Confirmatory Study of OPC-12759 Ophthalmic Solution",[85],"2013-03","2013-05",209,[1687],"Dry Eye",[1669],{"trials":1690,"activeCount":93},[],{"trials":1692,"activeCount":93},[],{"intervention":1694,"totalTrials":12,"cells":1695},"CDP870 400mg",{"EARLY_PHASE1":1696,"PHASE1":1698,"PHASE2":1700,"PHASE3":1702,"PHASE4":1716,"NA":1718},{"trials":1697,"activeCount":93},[],{"trials":1699,"activeCount":93},[],{"trials":1701,"activeCount":93},[],{"trials":1703,"activeCount":93},[1704],{"nctId":1705,"briefTitle":1706,"status":101,"phases":1707,"primaryCompletion":1708,"completion":1070,"start":1709,"enrollment":1710,"conditions":1711,"interventions":1713},"NCT00791999","Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)",[84,85],"2010-01","2008-11",316,[1712],"Rheumatoid Arthritis",[1694,1714,1715],"CDP870 200mg","CDP870 100mg",{"trials":1717,"activeCount":93},[],{"trials":1719,"activeCount":93},[],{"intervention":1714,"totalTrials":12,"cells":1721},{"EARLY_PHASE1":1722,"PHASE1":1724,"PHASE2":1726,"PHASE3":1728,"PHASE4":1734,"NA":1736},{"trials":1723,"activeCount":93},[],{"trials":1725,"activeCount":93},[],{"trials":1727,"activeCount":93},[],{"trials":1729,"activeCount":93},[1730],{"nctId":1705,"briefTitle":1706,"status":101,"phases":1731,"primaryCompletion":1708,"completion":1070,"start":1709,"enrollment":1710,"conditions":1732,"interventions":1733},[84,85],[1712],[1694,1714,1715],{"trials":1735,"activeCount":93},[],{"trials":1737,"activeCount":93},[],{"intervention":1715,"totalTrials":12,"cells":1739},{"EARLY_PHASE1":1740,"PHASE1":1742,"PHASE2":1744,"PHASE3":1746,"PHASE4":1752,"NA":1754},{"trials":1741,"activeCount":93},[],{"trials":1743,"activeCount":93},[],{"trials":1745,"activeCount":93},[],{"trials":1747,"activeCount":93},[1748],{"nctId":1705,"briefTitle":1706,"status":101,"phases":1749,"primaryCompletion":1708,"completion":1070,"start":1709,"enrollment":1710,"conditions":1750,"interventions":1751},[84,85],[1712],[1694,1714,1715],{"trials":1753,"activeCount":93},[],{"trials":1755,"activeCount":93},[],{"intervention":1029,"totalTrials":12,"cells":1757},{"EARLY_PHASE1":1758,"PHASE1":1760,"PHASE2":1762,"PHASE3":1764,"PHASE4":1770,"NA":1772},{"trials":1759,"activeCount":93},[],{"trials":1761,"activeCount":93},[],{"trials":1763,"activeCount":93},[],{"trials":1765,"activeCount":93},[1766],{"nctId":1021,"briefTitle":1022,"status":101,"phases":1767,"primaryCompletion":1024,"completion":1024,"start":1025,"enrollment":1026,"conditions":1768,"interventions":1769},[85],[18],[936,1029],{"trials":1771,"activeCount":93},[],{"trials":1773,"activeCount":93},[],{"intervention":1775,"totalTrials":12,"cells":1776},"Aripiprazole Low",{"EARLY_PHASE1":1777,"PHASE1":1779,"PHASE2":1781,"PHASE3":1783,"PHASE4":1795,"NA":1797},{"trials":1778,"activeCount":93},[],{"trials":1780,"activeCount":93},[],{"trials":1782,"activeCount":93},[],{"trials":1784,"activeCount":93},[1785],{"nctId":1786,"briefTitle":1787,"status":101,"phases":1788,"primaryCompletion":1789,"completion":1789,"start":643,"enrollment":1790,"conditions":1791,"interventions":1792},"NCT01942161","A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia",[84,85],"2014-11",106,[15],[1775,1793,1794],"Aripiprazole Mid","Aripiprazole High",{"trials":1796,"activeCount":93},[],{"trials":1798,"activeCount":93},[],{"intervention":1793,"totalTrials":12,"cells":1800},{"EARLY_PHASE1":1801,"PHASE1":1803,"PHASE2":1805,"PHASE3":1807,"PHASE4":1813,"NA":1815},{"trials":1802,"activeCount":93},[],{"trials":1804,"activeCount":93},[],{"trials":1806,"activeCount":93},[],{"trials":1808,"activeCount":93},[1809],{"nctId":1786,"briefTitle":1787,"status":101,"phases":1810,"primaryCompletion":1789,"completion":1789,"start":643,"enrollment":1790,"conditions":1811,"interventions":1812},[84,85],[15],[1775,1793,1794],{"trials":1814,"activeCount":93},[],{"trials":1816,"activeCount":93},[],{"intervention":1794,"totalTrials":12,"cells":1818},{"EARLY_PHASE1":1819,"PHASE1":1821,"PHASE2":1823,"PHASE3":1825,"PHASE4":1831,"NA":1833},{"trials":1820,"activeCount":93},[],{"trials":1822,"activeCount":93},[],{"trials":1824,"activeCount":93},[],{"trials":1826,"activeCount":93},[1827],{"nctId":1786,"briefTitle":1787,"status":101,"phases":1828,"primaryCompletion":1789,"completion":1789,"start":643,"enrollment":1790,"conditions":1829,"interventions":1830},[84,85],[15],[1775,1793,1794],{"trials":1832,"activeCount":93},[],{"trials":1834,"activeCount":93},[],{"intervention":1526,"totalTrials":12,"cells":1836},{"EARLY_PHASE1":1837,"PHASE1":1839,"PHASE2":1841,"PHASE3":1843,"PHASE4":1849,"NA":1851},{"trials":1838,"activeCount":93},[],{"trials":1840,"activeCount":93},[],{"trials":1842,"activeCount":93},[],{"trials":1844,"activeCount":93},[1845],{"nctId":1517,"briefTitle":1518,"status":101,"phases":1846,"primaryCompletion":1520,"completion":1521,"start":1522,"enrollment":1523,"conditions":1847,"interventions":1848},[85],[1102],[1506,1526],{"trials":1850,"activeCount":93},[],{"trials":1852,"activeCount":93},[],{"intervention":1854,"totalTrials":12,"cells":1855},"Each subject will subcutaneously self-administer TEV 48125 at 225 mg\u002F1.5 mL (150 mg\u002FmL) once monthly for a total of 2 doses.",{"EARLY_PHASE1":1856,"PHASE1":1858,"PHASE2":1860,"PHASE3":1862,"PHASE4":1872,"NA":1874},{"trials":1857,"activeCount":93},[],{"trials":1859,"activeCount":93},[],{"trials":1861,"activeCount":93},[],{"trials":1863,"activeCount":93},[1864],{"nctId":1865,"briefTitle":1866,"status":101,"phases":1867,"primaryCompletion":1439,"completion":1439,"start":1868,"enrollment":1869,"conditions":1870,"interventions":1871},"NCT04355117","A Safety Evaluation Trial of TEV-48125 Self-administered in Migraine Patients",[85],"2020-06-17",71,[33],[1854],{"trials":1873,"activeCount":93},[],{"trials":1875,"activeCount":93},[],{"intervention":1124,"totalTrials":12,"cells":1877},{"EARLY_PHASE1":1878,"PHASE1":1880,"PHASE2":1882,"PHASE3":1884,"PHASE4":1890,"NA":1892},{"trials":1879,"activeCount":93},[],{"trials":1881,"activeCount":93},[],{"trials":1883,"activeCount":93},[],{"trials":1885,"activeCount":93},[1886],{"nctId":1116,"briefTitle":1117,"status":101,"phases":1887,"primaryCompletion":1119,"completion":1119,"start":1120,"enrollment":1121,"conditions":1888,"interventions":1889},[85],[23],[1124,1125,108],{"trials":1891,"activeCount":93},[],{"trials":1893,"activeCount":93},[],{"intervention":1895,"totalTrials":12,"cells":1896},"OPC-14597",{"EARLY_PHASE1":1897,"PHASE1":1899,"PHASE2":1901,"PHASE3":1903,"PHASE4":1912,"NA":1914},{"trials":1898,"activeCount":93},[],{"trials":1900,"activeCount":93},[],{"trials":1902,"activeCount":93},[],{"trials":1904,"activeCount":93},[1905],{"nctId":1906,"briefTitle":1907,"status":101,"phases":1908,"primaryCompletion":658,"completion":658,"start":666,"enrollment":1909,"conditions":1910,"interventions":1911},"NCT00882362","Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder",[85],155,[21],[1895],{"trials":1913,"activeCount":93},[],{"trials":1915,"activeCount":93},[],{"intervention":1917,"totalTrials":12,"cells":1918},"CDP870",{"EARLY_PHASE1":1919,"PHASE1":1921,"PHASE2":1923,"PHASE3":1925,"PHASE4":1933,"NA":1935},{"trials":1920,"activeCount":93},[],{"trials":1922,"activeCount":93},[],{"trials":1924,"activeCount":93},[],{"trials":1926,"activeCount":93},[1927],{"nctId":1928,"briefTitle":1929,"status":101,"phases":1930,"primaryCompletion":1708,"completion":1708,"start":1709,"enrollment":968,"conditions":1931,"interventions":1932},"NCT00791921","Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)",[85],[1712],[1917],{"trials":1934,"activeCount":93},[],{"trials":1936,"activeCount":93},[],{"intervention":1083,"totalTrials":12,"cells":1938},{"EARLY_PHASE1":1939,"PHASE1":1941,"PHASE2":1943,"PHASE3":1945,"PHASE4":1951,"NA":1953},{"trials":1940,"activeCount":93},[],{"trials":1942,"activeCount":93},[],{"trials":1944,"activeCount":93},[],{"trials":1946,"activeCount":93},[1947],{"nctId":1075,"briefTitle":1076,"status":101,"phases":1948,"primaryCompletion":676,"completion":1078,"start":1079,"enrollment":1080,"conditions":1949,"interventions":1950},[85],[28],[1035,1083],{"trials":1952,"activeCount":93},[],{"trials":1954,"activeCount":93},[],{"intervention":1956,"totalTrials":12,"cells":1957},"OPC-41061 （Tolvaptan)",{"EARLY_PHASE1":1958,"PHASE1":1960,"PHASE2":1962,"PHASE3":1964,"PHASE4":1975,"NA":1977},{"trials":1959,"activeCount":93},[],{"trials":1961,"activeCount":93},[],{"trials":1963,"activeCount":93},[],{"trials":1965,"activeCount":93},[1966],{"nctId":1967,"briefTitle":1968,"status":101,"phases":1969,"primaryCompletion":1970,"completion":1970,"start":1971,"enrollment":1972,"conditions":1973,"interventions":1974},"NCT00544869","A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)",[85],"2009-02","2007-10",52,[891],[1956],{"trials":1976,"activeCount":93},[],{"trials":1978,"activeCount":93},[],{"intervention":1980,"totalTrials":150,"cells":1981},"OCV-501",{"EARLY_PHASE1":1982,"PHASE1":1984,"PHASE2":2000,"PHASE3":2011,"PHASE4":2013,"NA":2015},{"trials":1983,"activeCount":93},[],{"trials":1985,"activeCount":93},[1986,1992],{"nctId":1987,"briefTitle":1988,"status":101,"phases":1989,"primaryCompletion":1683,"completion":843,"start":433,"enrollment":597,"conditions":1990,"interventions":1991},"NCT01440920","A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients",[83],[25],[1980,1980,1980],{"nctId":1993,"briefTitle":1994,"status":101,"phases":1995,"primaryCompletion":1996,"completion":1996,"start":1997,"enrollment":1365,"conditions":1998,"interventions":1999},"NCT01475370","Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001)",[83],"2016-12-22","2012-01-24",[25],[1980],{"trials":2001,"activeCount":93},[2002],{"nctId":2003,"briefTitle":2004,"status":101,"phases":2005,"primaryCompletion":2006,"completion":2006,"start":2007,"enrollment":2008,"conditions":2009,"interventions":2010},"NCT01961882","A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia",[84],"2017-11-16","2013-10",134,[25],[1980],{"trials":2012,"activeCount":93},[],{"trials":2014,"activeCount":93},[],{"trials":2016,"activeCount":93},[],{"intervention":2018,"totalTrials":144,"cells":2019},"Calcium (13C)Carbonate",{"EARLY_PHASE1":2020,"PHASE1":2022,"PHASE2":2024,"PHASE3":2044,"PHASE4":2046,"NA":2048},{"trials":2021,"activeCount":93},[],{"trials":2023,"activeCount":93},[],{"trials":2025,"activeCount":93},[2026,2037],{"nctId":2027,"briefTitle":2028,"status":101,"phases":2029,"primaryCompletion":2030,"completion":2030,"start":2031,"enrollment":2032,"conditions":2033,"interventions":2035},"NCT03284177","A Trial of C13-CAC Breath Test in PPI Resistant GERD Patients",[84],"2018-12-04","2017-10-31",55,[2034],"Gastroesophageal Reflux Disease",[2018,2036],"Gastric acid inhibitors",{"nctId":2038,"briefTitle":2039,"status":101,"phases":2040,"primaryCompletion":823,"completion":823,"start":398,"enrollment":910,"conditions":2041,"interventions":2043},"NCT02225067","Comparison Study Between C13-CAC Breath Test and 24-hour Gastric pH Monitoring",[84],[2042,747],"Gastric Acid-related Diseases",[2018],{"trials":2045,"activeCount":93},[],{"trials":2047,"activeCount":93},[],{"trials":2049,"activeCount":93},[],{"intervention":1158,"totalTrials":12,"cells":2051},{"EARLY_PHASE1":2052,"PHASE1":2054,"PHASE2":2056,"PHASE3":2062,"PHASE4":2064,"NA":2066},{"trials":2053,"activeCount":93},[],{"trials":2055,"activeCount":93},[],{"trials":2057,"activeCount":93},[2058],{"nctId":1149,"briefTitle":1150,"status":101,"phases":2059,"primaryCompletion":1152,"completion":1153,"start":1154,"enrollment":1080,"conditions":2060,"interventions":2061},[84],[1156],[1140,1158,1159],{"trials":2063,"activeCount":93},[],{"trials":2065,"activeCount":93},[],{"trials":2067,"activeCount":93},[],{"intervention":1159,"totalTrials":12,"cells":2069},{"EARLY_PHASE1":2070,"PHASE1":2072,"PHASE2":2074,"PHASE3":2080,"PHASE4":2082,"NA":2084},{"trials":2071,"activeCount":93},[],{"trials":2073,"activeCount":93},[],{"trials":2075,"activeCount":93},[2076],{"nctId":1149,"briefTitle":1150,"status":101,"phases":2077,"primaryCompletion":1152,"completion":1153,"start":1154,"enrollment":1080,"conditions":2078,"interventions":2079},[84],[1156],[1140,1158,1159],{"trials":2081,"activeCount":93},[],{"trials":2083,"activeCount":93},[],{"trials":2085,"activeCount":93},[],{"intervention":2087,"totalTrials":12,"cells":2088},"2% Rebamipide liquid",{"EARLY_PHASE1":2089,"PHASE1":2091,"PHASE2":2093,"PHASE3":2104,"PHASE4":2106,"NA":2108},{"trials":2090,"activeCount":93},[],{"trials":2092,"activeCount":93},[],{"trials":2094,"activeCount":93},[2095],{"nctId":2096,"briefTitle":2097,"status":101,"phases":2098,"primaryCompletion":744,"completion":744,"start":432,"enrollment":2099,"conditions":2100,"interventions":2102},"NCT02085460","A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer",[84],94,[2101],"Head and Neck Cancer",[2087,2103],"4% Rebamipide liquid",{"trials":2105,"activeCount":93},[],{"trials":2107,"activeCount":93},[],{"trials":2109,"activeCount":93},[],{"intervention":2103,"totalTrials":12,"cells":2111},{"EARLY_PHASE1":2112,"PHASE1":2114,"PHASE2":2116,"PHASE3":2122,"PHASE4":2124,"NA":2126},{"trials":2113,"activeCount":93},[],{"trials":2115,"activeCount":93},[],{"trials":2117,"activeCount":93},[2118],{"nctId":2096,"briefTitle":2097,"status":101,"phases":2119,"primaryCompletion":744,"completion":744,"start":432,"enrollment":2099,"conditions":2120,"interventions":2121},[84],[2101],[2087,2103],{"trials":2123,"activeCount":93},[],{"trials":2125,"activeCount":93},[],{"trials":2127,"activeCount":93},[],{"intervention":2129,"totalTrials":12,"cells":2130},"OPC 131461 10mg group",{"EARLY_PHASE1":2131,"PHASE1":2133,"PHASE2":2135,"PHASE3":2150,"PHASE4":2152,"NA":2154},{"trials":2132,"activeCount":93},[],{"trials":2134,"activeCount":93},[],{"trials":2136,"activeCount":93},[2137],{"nctId":2138,"briefTitle":2139,"status":101,"phases":2140,"primaryCompletion":2141,"completion":2141,"start":2142,"enrollment":2143,"conditions":2144,"interventions":2146},"NCT05615363","A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])",[84],"2024-10-21","2023-01-10",157,[2145],"Cardiac Edema (CHF)",[2129,2147,2148,2149],"OPC 131461 5mg group","OPC 131461 2mg group","OPC 131461 1mg group",{"trials":2151,"activeCount":93},[],{"trials":2153,"activeCount":93},[],{"trials":2155,"activeCount":93},[],{"intervention":2147,"totalTrials":12,"cells":2157},{"EARLY_PHASE1":2158,"PHASE1":2160,"PHASE2":2162,"PHASE3":2168,"PHASE4":2170,"NA":2172},{"trials":2159,"activeCount":93},[],{"trials":2161,"activeCount":93},[],{"trials":2163,"activeCount":93},[2164],{"nctId":2138,"briefTitle":2139,"status":101,"phases":2165,"primaryCompletion":2141,"completion":2141,"start":2142,"enrollment":2143,"conditions":2166,"interventions":2167},[84],[2145],[2129,2147,2148,2149],{"trials":2169,"activeCount":93},[],{"trials":2171,"activeCount":93},[],{"trials":2173,"activeCount":93},[],{"intervention":2148,"totalTrials":12,"cells":2175},{"EARLY_PHASE1":2176,"PHASE1":2178,"PHASE2":2180,"PHASE3":2186,"PHASE4":2188,"NA":2190},{"trials":2177,"activeCount":93},[],{"trials":2179,"activeCount":93},[],{"trials":2181,"activeCount":93},[2182],{"nctId":2138,"briefTitle":2139,"status":101,"phases":2183,"primaryCompletion":2141,"completion":2141,"start":2142,"enrollment":2143,"conditions":2184,"interventions":2185},[84],[2145],[2129,2147,2148,2149],{"trials":2187,"activeCount":93},[],{"trials":2189,"activeCount":93},[],{"trials":2191,"activeCount":93},[],{"intervention":2149,"totalTrials":12,"cells":2193},{"EARLY_PHASE1":2194,"PHASE1":2196,"PHASE2":2198,"PHASE3":2204,"PHASE4":2206,"NA":2208},{"trials":2195,"activeCount":93},[],{"trials":2197,"activeCount":93},[],{"trials":2199,"activeCount":93},[2200],{"nctId":2138,"briefTitle":2139,"status":101,"phases":2201,"primaryCompletion":2141,"completion":2141,"start":2142,"enrollment":2143,"conditions":2202,"interventions":2203},[84],[2145],[2129,2147,2148,2149],{"trials":2205,"activeCount":93},[],{"trials":2207,"activeCount":93},[],{"trials":2209,"activeCount":93},[],{"intervention":2211,"totalTrials":12,"cells":2212},"OPS-2071",{"EARLY_PHASE1":2213,"PHASE1":2215,"PHASE2":2217,"PHASE3":2228,"PHASE4":2230,"NA":2232},{"trials":2214,"activeCount":93},[],{"trials":2216,"activeCount":93},[],{"trials":2218,"activeCount":93},[2219],{"nctId":2220,"briefTitle":2221,"status":101,"phases":2222,"primaryCompletion":2223,"completion":2223,"start":2224,"enrollment":870,"conditions":2225,"interventions":2227},"NCT02473393","A Clinical Trial to Assess Three Different Doses of OPS-2071 in Patients With Bacterial Enteritis",[84],"2017-03-14","2015-08-20",[2226],"Bacterial Enteritis",[2211],{"trials":2229,"activeCount":93},[],{"trials":2231,"activeCount":93},[],{"trials":2233,"activeCount":93},[],{"intervention":1062,"totalTrials":12,"cells":2235},{"EARLY_PHASE1":2236,"PHASE1":2238,"PHASE2":2240,"PHASE3":2246,"PHASE4":2248,"NA":2250},{"trials":2237,"activeCount":93},[],{"trials":2239,"activeCount":93},[],{"trials":2241,"activeCount":93},[2242],{"nctId":1052,"briefTitle":1053,"status":101,"phases":2243,"primaryCompletion":1055,"completion":1056,"start":908,"enrollment":1057,"conditions":2244,"interventions":2245},[84],[1059],[1061,1062],{"trials":2247,"activeCount":93},[],{"trials":2249,"activeCount":93},[],{"trials":2251,"activeCount":93},[],{"intervention":2253,"totalTrials":12,"cells":2254},"0.5% OPC-12759",{"EARLY_PHASE1":2255,"PHASE1":2257,"PHASE2":2259,"PHASE3":2271,"PHASE4":2273,"NA":2275},{"trials":2256,"activeCount":93},[],{"trials":2258,"activeCount":93},[],{"trials":2260,"activeCount":93},[2261],{"nctId":2262,"briefTitle":2263,"status":101,"phases":2264,"primaryCompletion":851,"completion":2265,"start":985,"enrollment":2266,"conditions":2267,"interventions":2268},"NCT00234078","Dose-response Study of OPC-12759 Ophthalmic Suspension",[84],"2007-03",290,[28],[2253,2269,2270],"1% OPC-12759","2% OPC-12759",{"trials":2272,"activeCount":93},[],{"trials":2274,"activeCount":93},[],{"trials":2276,"activeCount":93},[],{"intervention":2269,"totalTrials":12,"cells":2278},{"EARLY_PHASE1":2279,"PHASE1":2281,"PHASE2":2283,"PHASE3":2289,"PHASE4":2291,"NA":2293},{"trials":2280,"activeCount":93},[],{"trials":2282,"activeCount":93},[],{"trials":2284,"activeCount":93},[2285],{"nctId":2262,"briefTitle":2263,"status":101,"phases":2286,"primaryCompletion":851,"completion":2265,"start":985,"enrollment":2266,"conditions":2287,"interventions":2288},[84],[28],[2253,2269,2270],{"trials":2290,"activeCount":93},[],{"trials":2292,"activeCount":93},[],{"trials":2294,"activeCount":93},[],{"intervention":2270,"totalTrials":12,"cells":2296},{"EARLY_PHASE1":2297,"PHASE1":2299,"PHASE2":2301,"PHASE3":2307,"PHASE4":2309,"NA":2311},{"trials":2298,"activeCount":93},[],{"trials":2300,"activeCount":93},[],{"trials":2302,"activeCount":93},[2303],{"nctId":2262,"briefTitle":2263,"status":101,"phases":2304,"primaryCompletion":851,"completion":2265,"start":985,"enrollment":2266,"conditions":2305,"interventions":2306},[84],[28],[2253,2269,2270],{"trials":2308,"activeCount":93},[],{"trials":2310,"activeCount":93},[],{"trials":2312,"activeCount":93},[],{"intervention":2314,"totalTrials":12,"cells":2315},"OPB-31121",{"EARLY_PHASE1":2316,"PHASE1":2318,"PHASE2":2320,"PHASE3":2332,"PHASE4":2334,"NA":2336},{"trials":2317,"activeCount":93},[],{"trials":2319,"activeCount":93},[],{"trials":2321,"activeCount":93},[2322],{"nctId":2323,"briefTitle":2324,"status":101,"phases":2325,"primaryCompletion":432,"completion":432,"start":2326,"enrollment":2327,"conditions":2328,"interventions":2330},"NCT01406574","Phase I\u002FII Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma",[83,84],"2011-07",23,[2329],"Hepatocellular Carcinoma",[2314,2331],"OPB-31121 phase2",{"trials":2333,"activeCount":93},[],{"trials":2335,"activeCount":93},[],{"trials":2337,"activeCount":93},[],{"intervention":2331,"totalTrials":12,"cells":2339},{"EARLY_PHASE1":2340,"PHASE1":2342,"PHASE2":2344,"PHASE3":2350,"PHASE4":2352,"NA":2354},{"trials":2341,"activeCount":93},[],{"trials":2343,"activeCount":93},[],{"trials":2345,"activeCount":93},[2346],{"nctId":2323,"briefTitle":2324,"status":101,"phases":2347,"primaryCompletion":432,"completion":432,"start":2326,"enrollment":2327,"conditions":2348,"interventions":2349},[83,84],[2329],[2314,2331],{"trials":2351,"activeCount":93},[],{"trials":2353,"activeCount":93},[],{"trials":2355,"activeCount":93},[],{"intervention":2357,"totalTrials":12,"cells":2358},"1% OPC-12759 ophthalmic suspension",{"EARLY_PHASE1":2359,"PHASE1":2361,"PHASE2":2363,"PHASE3":2375,"PHASE4":2377,"NA":2379},{"trials":2360,"activeCount":93},[],{"trials":2362,"activeCount":93},[],{"trials":2364,"activeCount":93},[2365],{"nctId":2366,"briefTitle":2367,"status":101,"phases":2368,"primaryCompletion":2369,"completion":967,"start":2370,"enrollment":2371,"conditions":2372,"interventions":2373},"NCT00475319","Late Phase 2 Study of OPC-12759 Ophthalmic Suspension",[84],"2008-03","2007-05",308,[28],[2357,2374],"2% OPC-12759 ophthalmic suspension",{"trials":2376,"activeCount":93},[],{"trials":2378,"activeCount":93},[],{"trials":2380,"activeCount":93},[],{"intervention":2374,"totalTrials":12,"cells":2382},{"EARLY_PHASE1":2383,"PHASE1":2385,"PHASE2":2387,"PHASE3":2393,"PHASE4":2395,"NA":2397},{"trials":2384,"activeCount":93},[],{"trials":2386,"activeCount":93},[],{"trials":2388,"activeCount":93},[2389],{"nctId":2366,"briefTitle":2367,"status":101,"phases":2390,"primaryCompletion":2369,"completion":967,"start":2370,"enrollment":2371,"conditions":2391,"interventions":2392},[84],[28],[2357,2374],{"trials":2394,"activeCount":93},[],{"trials":2396,"activeCount":93},[],{"trials":2398,"activeCount":93},[],{"intervention":2400,"totalTrials":12,"cells":2401},"13C-uracil",{"EARLY_PHASE1":2402,"PHASE1":2404,"PHASE2":2406,"PHASE3":2416,"PHASE4":2418,"NA":2420},{"trials":2403,"activeCount":93},[],{"trials":2405,"activeCount":93},[],{"trials":2407,"activeCount":93},[2408],{"nctId":2409,"briefTitle":2410,"status":101,"phases":2411,"primaryCompletion":869,"completion":880,"start":843,"enrollment":844,"conditions":2412,"interventions":2414},"NCT01677338","Phase 2 Study to Evaluate the Preliminary Performance of the C13-URA Breath Test Kit in Dyspeptic Subjects",[84],[2413],"Dyspeptic Subjects",[2400,2415],"99mTc sulfur colloid",{"trials":2417,"activeCount":93},[],{"trials":2419,"activeCount":93},[],{"trials":2421,"activeCount":93},[],{"intervention":2415,"totalTrials":12,"cells":2423},{"EARLY_PHASE1":2424,"PHASE1":2426,"PHASE2":2428,"PHASE3":2434,"PHASE4":2436,"NA":2438},{"trials":2425,"activeCount":93},[],{"trials":2427,"activeCount":93},[],{"trials":2429,"activeCount":93},[2430],{"nctId":2409,"briefTitle":2410,"status":101,"phases":2431,"primaryCompletion":869,"completion":880,"start":843,"enrollment":844,"conditions":2432,"interventions":2433},[84],[2413],[2400,2415],{"trials":2435,"activeCount":93},[],{"trials":2437,"activeCount":93},[],{"trials":2439,"activeCount":93},[],{"intervention":2441,"totalTrials":12,"cells":2442},"tetomilast",{"EARLY_PHASE1":2443,"PHASE1":2445,"PHASE2":2447,"PHASE3":2457,"PHASE4":2459,"NA":2461},{"trials":2444,"activeCount":93},[],{"trials":2446,"activeCount":93},[],{"trials":2448,"activeCount":93},[2449],{"nctId":2450,"briefTitle":2451,"status":101,"phases":2452,"primaryCompletion":1281,"completion":1281,"start":666,"enrollment":2453,"conditions":2454,"interventions":2456},"NCT00917150","To Investigate the Efficacy and Safety of OPC-6535 in Chronic Obstructive Pulmonary Disease (COPD) Patients",[84],771,[2455],"Chronic Obstructive Pulmonary Disease",[2441,2441,2441],{"trials":2458,"activeCount":93},[],{"trials":2460,"activeCount":93},[],{"trials":2462,"activeCount":93},[],{"intervention":2464,"totalTrials":12,"cells":2465},"OPC-41061 7.5mg",{"EARLY_PHASE1":2466,"PHASE1":2468,"PHASE2":2470,"PHASE3":2481,"PHASE4":2483,"NA":2485},{"trials":2467,"activeCount":93},[],{"trials":2469,"activeCount":93},[],{"trials":2471,"activeCount":93},[2472],{"nctId":2473,"briefTitle":2474,"status":101,"phases":2475,"primaryCompletion":888,"completion":888,"start":697,"enrollment":710,"conditions":2476,"interventions":2477},"NCT00479336","A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema",[84],[901],[2464,2478,2479,2480],"OPC-41061 placebo","OPC-41061 15mg","OPC-41601 30mg",{"trials":2482,"activeCount":93},[],{"trials":2484,"activeCount":93},[],{"trials":2486,"activeCount":93},[],{"intervention":2478,"totalTrials":12,"cells":2488},{"EARLY_PHASE1":2489,"PHASE1":2491,"PHASE2":2493,"PHASE3":2499,"PHASE4":2501,"NA":2503},{"trials":2490,"activeCount":93},[],{"trials":2492,"activeCount":93},[],{"trials":2494,"activeCount":93},[2495],{"nctId":2473,"briefTitle":2474,"status":101,"phases":2496,"primaryCompletion":888,"completion":888,"start":697,"enrollment":710,"conditions":2497,"interventions":2498},[84],[901],[2464,2478,2479,2480],{"trials":2500,"activeCount":93},[],{"trials":2502,"activeCount":93},[],{"trials":2504,"activeCount":93},[],{"intervention":2479,"totalTrials":12,"cells":2506},{"EARLY_PHASE1":2507,"PHASE1":2509,"PHASE2":2511,"PHASE3":2517,"PHASE4":2519,"NA":2521},{"trials":2508,"activeCount":93},[],{"trials":2510,"activeCount":93},[],{"trials":2512,"activeCount":93},[2513],{"nctId":2473,"briefTitle":2474,"status":101,"phases":2514,"primaryCompletion":888,"completion":888,"start":697,"enrollment":710,"conditions":2515,"interventions":2516},[84],[901],[2464,2478,2479,2480],{"trials":2518,"activeCount":93},[],{"trials":2520,"activeCount":93},[],{"trials":2522,"activeCount":93},[],{"intervention":2480,"totalTrials":12,"cells":2524},{"EARLY_PHASE1":2525,"PHASE1":2527,"PHASE2":2529,"PHASE3":2535,"PHASE4":2537,"NA":2539},{"trials":2526,"activeCount":93},[],{"trials":2528,"activeCount":93},[],{"trials":2530,"activeCount":93},[2531],{"nctId":2473,"briefTitle":2474,"status":101,"phases":2532,"primaryCompletion":888,"completion":888,"start":697,"enrollment":710,"conditions":2533,"interventions":2534},[84],[901],[2464,2478,2479,2480],{"trials":2536,"activeCount":93},[],{"trials":2538,"activeCount":93},[],{"trials":2540,"activeCount":93},[],{"intervention":2036,"totalTrials":12,"cells":2542},{"EARLY_PHASE1":2543,"PHASE1":2545,"PHASE2":2547,"PHASE3":2553,"PHASE4":2555,"NA":2557},{"trials":2544,"activeCount":93},[],{"trials":2546,"activeCount":93},[],{"trials":2548,"activeCount":93},[2549],{"nctId":2027,"briefTitle":2028,"status":101,"phases":2550,"primaryCompletion":2030,"completion":2030,"start":2031,"enrollment":2032,"conditions":2551,"interventions":2552},[84],[2034],[2018,2036],{"trials":2554,"activeCount":93},[],{"trials":2556,"activeCount":93},[],{"trials":2558,"activeCount":93},[],{"intervention":2560,"totalTrials":12,"cells":2561},"OPC-64005 20 mg , Once-daily",{"EARLY_PHASE1":2562,"PHASE1":2564,"PHASE2":2566,"PHASE3":2579,"PHASE4":2581,"NA":2583},{"trials":2563,"activeCount":93},[],{"trials":2565,"activeCount":93},[],{"trials":2567,"activeCount":93},[2568],{"nctId":2569,"briefTitle":2570,"status":101,"phases":2571,"primaryCompletion":2572,"completion":2573,"start":2574,"enrollment":2575,"conditions":2576,"interventions":2577},"NCT04244253","A Phase 2 Trial of OPC-64005 for Major Depressive Disorder",[84],"2022-02-08","2022-02-25","2020-03-03",273,[21],[2560,2578],"OPC-64005 10 mg , Once-daily",{"trials":2580,"activeCount":93},[],{"trials":2582,"activeCount":93},[],{"trials":2584,"activeCount":93},[],{"intervention":2578,"totalTrials":12,"cells":2586},{"EARLY_PHASE1":2587,"PHASE1":2589,"PHASE2":2591,"PHASE3":2597,"PHASE4":2599,"NA":2601},{"trials":2588,"activeCount":93},[],{"trials":2590,"activeCount":93},[],{"trials":2592,"activeCount":93},[2593],{"nctId":2569,"briefTitle":2570,"status":101,"phases":2594,"primaryCompletion":2572,"completion":2573,"start":2574,"enrollment":2575,"conditions":2595,"interventions":2596},[84],[21],[2560,2578],{"trials":2598,"activeCount":93},[],{"trials":2600,"activeCount":93},[],{"trials":2602,"activeCount":93},[],{"intervention":2604,"totalTrials":12,"cells":2605},"ASTX660",{"EARLY_PHASE1":2606,"PHASE1":2608,"PHASE2":2610,"PHASE3":2622,"PHASE4":2624,"NA":2626},{"trials":2607,"activeCount":93},[],{"trials":2609,"activeCount":93},[],{"trials":2611,"activeCount":93},[2612],{"nctId":2613,"briefTitle":2614,"status":1240,"phases":2615,"primaryCompletion":2616,"completion":2616,"start":2617,"enrollment":2618,"conditions":2619,"interventions":2621},"NCT04362007","A Phase I\u002FII Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma",[83,84],"2024-11-30","2020-07-14",8,[2620],"Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia\u002FLymphoma(ATLL)",[2604,2604,2604],{"trials":2623,"activeCount":93},[],{"trials":2625,"activeCount":93},[],{"trials":2627,"activeCount":93},[],{"intervention":2629,"totalTrials":12,"cells":2630},"OPC-18",{"EARLY_PHASE1":2631,"PHASE1":2633,"PHASE2":2635,"PHASE3":2644,"PHASE4":2646,"NA":2648},{"trials":2632,"activeCount":93},[],{"trials":2634,"activeCount":93},[],{"trials":2636,"activeCount":93},[2637],{"nctId":2638,"briefTitle":2639,"status":101,"phases":2640,"primaryCompletion":1708,"completion":1708,"start":889,"enrollment":422,"conditions":2641,"interventions":2642},"NCT00524498","A Phase II Study of a Continuous Hepatic Arterial Infusion Combination Therapy With OPC-18 and 5-FU in Patients With Highly Advanced Hepatocellular Carcinoma",[84],[2329],[2629,2643],"cisplatin",{"trials":2645,"activeCount":93},[],{"trials":2647,"activeCount":93},[],{"trials":2649,"activeCount":93},[],{"intervention":2643,"totalTrials":12,"cells":2651},{"EARLY_PHASE1":2652,"PHASE1":2654,"PHASE2":2656,"PHASE3":2662,"PHASE4":2664,"NA":2666},{"trials":2653,"activeCount":93},[],{"trials":2655,"activeCount":93},[],{"trials":2657,"activeCount":93},[2658],{"nctId":2638,"briefTitle":2639,"status":101,"phases":2659,"primaryCompletion":1708,"completion":1708,"start":889,"enrollment":422,"conditions":2660,"interventions":2661},[84],[2329],[2629,2643],{"trials":2663,"activeCount":93},[],{"trials":2665,"activeCount":93},[],{"trials":2667,"activeCount":93},[],{"intervention":2669,"totalTrials":12,"cells":2670},"OPC-249",{"EARLY_PHASE1":2671,"PHASE1":2673,"PHASE2":2675,"PHASE3":2687,"PHASE4":2689,"NA":2691},{"trials":2672,"activeCount":93},[],{"trials":2674,"activeCount":93},[],{"trials":2676,"activeCount":93},[2677],{"nctId":2678,"briefTitle":2679,"status":101,"phases":2680,"primaryCompletion":2681,"completion":1079,"start":2682,"enrollment":2683,"conditions":2684,"interventions":2686},"NCT00504426","Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis",[84],"2008-07","2007-07",101,[2685],"Pain Due to Osteoporosis",[2669],{"trials":2688,"activeCount":93},[],{"trials":2690,"activeCount":93},[],{"trials":2692,"activeCount":93},[],{"intervention":2694,"totalTrials":12,"cells":2695},"14C-OPS-2071",{"EARLY_PHASE1":2696,"PHASE1":2698,"PHASE2":2706,"PHASE3":2708,"PHASE4":2710,"NA":2712},{"trials":2697,"activeCount":93},[],{"trials":2699,"activeCount":93},[2700],{"nctId":2701,"briefTitle":2702,"status":101,"phases":2703,"primaryCompletion":744,"completion":744,"start":1376,"enrollment":2618,"conditions":2704,"interventions":2705},"NCT02440633","A Phase 1,Open -Label Study to Assess the Absorption, Metabolism and Excretion of 14C-OPS-2071 Following a Single Oral Dose to Healthy Male Japanese Subjects",[83],[2226],[2694],{"trials":2707,"activeCount":93},[],{"trials":2709,"activeCount":93},[],{"trials":2711,"activeCount":93},[],{"trials":2713,"activeCount":93},[],{"intervention":2715,"totalTrials":12,"cells":2716},"2mg conventional tablet, once-weekly",{"EARLY_PHASE1":2717,"PHASE1":2719,"PHASE2":2730,"PHASE3":2732,"PHASE4":2734,"NA":2736},{"trials":2718,"activeCount":93},[],{"trials":2720,"activeCount":93},[2721],{"nctId":2722,"briefTitle":2723,"status":101,"phases":2724,"primaryCompletion":2725,"completion":2726,"start":2727,"enrollment":105,"conditions":2728,"interventions":2729},"NCT04118127","A Clinical Pharmacology Trial of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral Doses",[83],"2021-02-16","2021-03-03","2019-10-17",[15],[2715],{"trials":2731,"activeCount":93},[],{"trials":2733,"activeCount":93},[],{"trials":2735,"activeCount":93},[],{"trials":2737,"activeCount":93},[],{"intervention":2739,"totalTrials":12,"cells":2740},"[2-13C] uracil",{"EARLY_PHASE1":2741,"PHASE1":2743,"PHASE2":2754,"PHASE3":2756,"PHASE4":2758,"NA":2760},{"trials":2742,"activeCount":93},[],{"trials":2744,"activeCount":93},[2745],{"nctId":2746,"briefTitle":2747,"status":101,"phases":2748,"primaryCompletion":2749,"completion":2749,"start":909,"enrollment":2618,"conditions":2750,"interventions":2752},"NCT01074710","Safety and Pharmacokinetic Study of C13-URA in Healthy Volunteers",[83],"2010-05",[2751],"Gastroparesis",[2739,2753],"[2-13C] uracil, placebo",{"trials":2755,"activeCount":93},[],{"trials":2757,"activeCount":93},[],{"trials":2759,"activeCount":93},[],{"trials":2761,"activeCount":93},[],{"intervention":2753,"totalTrials":12,"cells":2763},{"EARLY_PHASE1":2764,"PHASE1":2766,"PHASE2":2772,"PHASE3":2774,"PHASE4":2776,"NA":2778},{"trials":2765,"activeCount":93},[],{"trials":2767,"activeCount":93},[2768],{"nctId":2746,"briefTitle":2747,"status":101,"phases":2769,"primaryCompletion":2749,"completion":2749,"start":909,"enrollment":2618,"conditions":2770,"interventions":2771},[83],[2751],[2739,2753],{"trials":2773,"activeCount":93},[],{"trials":2775,"activeCount":93},[],{"trials":2777,"activeCount":93},[],{"trials":2779,"activeCount":93},[],{"intervention":1048,"totalTrials":12,"cells":2781},{"EARLY_PHASE1":2782,"PHASE1":2784,"PHASE2":2790,"PHASE3":2792,"PHASE4":2794,"NA":2796},{"trials":2783,"activeCount":93},[],{"trials":2785,"activeCount":93},[2786],{"nctId":1042,"briefTitle":1043,"status":101,"phases":2787,"primaryCompletion":908,"completion":897,"start":1045,"enrollment":334,"conditions":2788,"interventions":2789},[83],[28],[1048,1035],{"trials":2791,"activeCount":93},[],{"trials":2793,"activeCount":93},[],{"trials":2795,"activeCount":93},[],{"trials":2797,"activeCount":93},[],{"intervention":2799,"totalTrials":12,"cells":2800},"(14C)-OPC-61815",{"EARLY_PHASE1":2801,"PHASE1":2803,"PHASE2":2813,"PHASE3":2815,"PHASE4":2817,"NA":2819},{"trials":2802,"activeCount":93},[],{"trials":2804,"activeCount":93},[2805],{"nctId":2806,"briefTitle":2807,"status":101,"phases":2808,"primaryCompletion":2809,"completion":2809,"start":2810,"enrollment":2618,"conditions":2811,"interventions":2812},"NCT04182958","A Phase I, Open-Label Trial to Assess the Absorption, Metabolism, and Excretion of (14C)-OPC-61815 in Healthy Male Japanese Subjects",[83],"2019-12-19","2019-11-25",[814],[2799],{"trials":2814,"activeCount":93},[],{"trials":2816,"activeCount":93},[],{"trials":2818,"activeCount":93},[],{"trials":2820,"activeCount":93},[],{"intervention":2822,"totalTrials":12,"cells":2823},"OPC-108459",{"EARLY_PHASE1":2824,"PHASE1":2826,"PHASE2":2835,"PHASE3":2837,"PHASE4":2839,"NA":2841},{"trials":2825,"activeCount":93},[],{"trials":2827,"activeCount":93},[2828],{"nctId":2829,"briefTitle":2830,"status":101,"phases":2831,"primaryCompletion":744,"completion":744,"start":842,"enrollment":1100,"conditions":2832,"interventions":2834},"NCT02069119","A Trial to Determine the Safety, Pharmacokinetics, and Efficacy of OPC-108459 Administered as a Single Intravenous Dose to Patients With Paroxysmal or Persistent Atrial Fibrillation (AF)",[83],[2833],"Atrial Fibrillation",[2822],{"trials":2836,"activeCount":93},[],{"trials":2838,"activeCount":93},[],{"trials":2840,"activeCount":93},[],{"trials":2842,"activeCount":93},[],{"intervention":1328,"totalTrials":12,"cells":2844},{"EARLY_PHASE1":2845,"PHASE1":2847,"PHASE2":2853,"PHASE3":2855,"PHASE4":2857,"NA":2859},{"trials":2846,"activeCount":93},[],{"trials":2848,"activeCount":93},[2849],{"nctId":1319,"briefTitle":1320,"status":101,"phases":2850,"primaryCompletion":1322,"completion":1322,"start":1323,"enrollment":1324,"conditions":2851,"interventions":2852},[83],[1326],[1312,1328],{"trials":2854,"activeCount":93},[],{"trials":2856,"activeCount":93},[],{"trials":2858,"activeCount":93},[],{"trials":2860,"activeCount":93},[],{"intervention":1104,"totalTrials":12,"cells":2862},{"EARLY_PHASE1":2863,"PHASE1":2865,"PHASE2":2871,"PHASE3":2873,"PHASE4":2875,"NA":2877},{"trials":2864,"activeCount":93},[],{"trials":2866,"activeCount":93},[2867],{"nctId":1095,"briefTitle":1096,"status":101,"phases":2868,"primaryCompletion":1098,"completion":1098,"start":1099,"enrollment":1100,"conditions":2869,"interventions":2870},[83],[1102],[1104,1105,1106,108],{"trials":2872,"activeCount":93},[],{"trials":2874,"activeCount":93},[],{"trials":2876,"activeCount":93},[],{"trials":2878,"activeCount":93},[],{"intervention":1105,"totalTrials":12,"cells":2880},{"EARLY_PHASE1":2881,"PHASE1":2883,"PHASE2":2889,"PHASE3":2891,"PHASE4":2893,"NA":2895},{"trials":2882,"activeCount":93},[],{"trials":2884,"activeCount":93},[2885],{"nctId":1095,"briefTitle":1096,"status":101,"phases":2886,"primaryCompletion":1098,"completion":1098,"start":1099,"enrollment":1100,"conditions":2887,"interventions":2888},[83],[1102],[1104,1105,1106,108],{"trials":2890,"activeCount":93},[],{"trials":2892,"activeCount":93},[],{"trials":2894,"activeCount":93},[],{"trials":2896,"activeCount":93},[],{"intervention":1106,"totalTrials":12,"cells":2898},{"EARLY_PHASE1":2899,"PHASE1":2901,"PHASE2":2907,"PHASE3":2909,"PHASE4":2911,"NA":2913},{"trials":2900,"activeCount":93},[],{"trials":2902,"activeCount":93},[2903],{"nctId":1095,"briefTitle":1096,"status":101,"phases":2904,"primaryCompletion":1098,"completion":1098,"start":1099,"enrollment":1100,"conditions":2905,"interventions":2906},[83],[1102],[1104,1105,1106,108],{"trials":2908,"activeCount":93},[],{"trials":2910,"activeCount":93},[],{"trials":2912,"activeCount":93},[],{"trials":2914,"activeCount":93},[],{"intervention":2916,"totalTrials":12,"cells":2917},"Topical steroid",{"EARLY_PHASE1":2918,"PHASE1":2920,"PHASE2":2931,"PHASE3":2933,"PHASE4":2935,"NA":2937},{"trials":2919,"activeCount":93},[],{"trials":2921,"activeCount":93},[2922],{"nctId":2923,"briefTitle":2924,"status":101,"phases":2925,"primaryCompletion":2926,"completion":1055,"start":1260,"enrollment":2927,"conditions":2928,"interventions":2929},"NCT01737931","A Trial to Explore Symptomatic Therapy for Application Site Reaction to SPM962 in Healthy Subject",[83],"2012-10",120,[747],[2916,2930],"Topical antihistamine",{"trials":2932,"activeCount":93},[],{"trials":2934,"activeCount":93},[],{"trials":2936,"activeCount":93},[],{"trials":2938,"activeCount":93},[],{"intervention":2930,"totalTrials":12,"cells":2940},{"EARLY_PHASE1":2941,"PHASE1":2943,"PHASE2":2949,"PHASE3":2951,"PHASE4":2953,"NA":2955},{"trials":2942,"activeCount":93},[],{"trials":2944,"activeCount":93},[2945],{"nctId":2923,"briefTitle":2924,"status":101,"phases":2946,"primaryCompletion":2926,"completion":1055,"start":1260,"enrollment":2927,"conditions":2947,"interventions":2948},[83],[747],[2916,2930],{"trials":2950,"activeCount":93},[],{"trials":2952,"activeCount":93},[],{"trials":2954,"activeCount":93},[],{"trials":2956,"activeCount":93},[],{"intervention":2958,"totalTrials":12,"cells":2959},"OCV-103 and OCV-104",{"EARLY_PHASE1":2960,"PHASE1":2962,"PHASE2":2972,"PHASE3":2974,"PHASE4":2976,"NA":2978},{"trials":2961,"activeCount":93},[],{"trials":2963,"activeCount":93},[2964],{"nctId":2965,"briefTitle":2966,"status":101,"phases":2967,"primaryCompletion":1303,"completion":1303,"start":1683,"enrollment":2968,"conditions":2969,"interventions":2971},"NCT01801930","A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer",[83],24,[2970],"Colorectal Cancer",[2958,2958,2958,2958],{"trials":2973,"activeCount":93},[],{"trials":2975,"activeCount":93},[],{"trials":2977,"activeCount":93},[],{"trials":2979,"activeCount":93},[],{"intervention":1430,"totalTrials":12,"cells":2981},{"EARLY_PHASE1":2982,"PHASE1":2984,"PHASE2":2990,"PHASE3":2992,"PHASE4":2994,"NA":2996},{"trials":2983,"activeCount":93},[],{"trials":2985,"activeCount":93},[2986],{"nctId":1421,"briefTitle":1422,"status":101,"phases":2987,"primaryCompletion":1424,"completion":1424,"start":1303,"enrollment":1425,"conditions":2988,"interventions":2989},[83],[23],[1428,1429,1430],{"trials":2991,"activeCount":93},[],{"trials":2993,"activeCount":93},[],{"trials":2995,"activeCount":93},[],{"trials":2997,"activeCount":93},[],{"intervention":2999,"totalTrials":12,"cells":3000},"OPB-111077",{"EARLY_PHASE1":3001,"PHASE1":3003,"PHASE2":3015,"PHASE3":3017,"PHASE4":3019,"NA":3021},{"trials":3002,"activeCount":93},[],{"trials":3004,"activeCount":93},[3005],{"nctId":3006,"briefTitle":3007,"status":101,"phases":3008,"primaryCompletion":3009,"completion":3010,"start":1220,"enrollment":3011,"conditions":3012,"interventions":3014},"NCT04049825","A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r\u002Fr DLBCL",[83],"2025-03-25","2026-01-19",36,[3013],"Relapsed or Refractory Diffuse Large B-cell Lymphoma",[2999,2999],{"trials":3016,"activeCount":93},[],{"trials":3018,"activeCount":93},[],{"trials":3020,"activeCount":93},[],{"trials":3022,"activeCount":93},[],{"intervention":3024,"totalTrials":12,"cells":3025},"SGI-110",{"EARLY_PHASE1":3026,"PHASE1":3028,"PHASE2":3040,"PHASE3":3042,"PHASE4":3044,"NA":3046},{"trials":3027,"activeCount":93},[],{"trials":3029,"activeCount":93},[3030],{"nctId":3031,"briefTitle":3032,"status":101,"phases":3033,"primaryCompletion":3034,"completion":3035,"start":3036,"enrollment":3037,"conditions":3038,"interventions":3039},"NCT02293993","Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia",[83],"2017-06-14","2019-05-31","2015-01-07",21,[25],[3024],{"trials":3041,"activeCount":93},[],{"trials":3043,"activeCount":93},[],{"trials":3045,"activeCount":93},[],{"trials":3047,"activeCount":93},[],{"intervention":749,"totalTrials":12,"cells":3049},{"EARLY_PHASE1":3050,"PHASE1":3052,"PHASE2":3058,"PHASE3":3060,"PHASE4":3062,"NA":3064},{"trials":3051,"activeCount":93},[],{"trials":3053,"activeCount":93},[3054],{"nctId":740,"briefTitle":741,"status":101,"phases":3055,"primaryCompletion":743,"completion":743,"start":744,"enrollment":745,"conditions":3056,"interventions":3057},[83],[747],[733,749,750],{"trials":3059,"activeCount":93},[],{"trials":3061,"activeCount":93},[],{"trials":3063,"activeCount":93},[],{"trials":3065,"activeCount":93},[],{"intervention":750,"totalTrials":12,"cells":3067},{"EARLY_PHASE1":3068,"PHASE1":3070,"PHASE2":3076,"PHASE3":3078,"PHASE4":3080,"NA":3082},{"trials":3069,"activeCount":93},[],{"trials":3071,"activeCount":93},[3072],{"nctId":740,"briefTitle":741,"status":101,"phases":3073,"primaryCompletion":743,"completion":743,"start":744,"enrollment":745,"conditions":3074,"interventions":3075},[83],[747],[733,749,750],{"trials":3077,"activeCount":93},[],{"trials":3079,"activeCount":93},[],{"trials":3081,"activeCount":93},[],{"trials":3083,"activeCount":93},[],{"intervention":3085,"totalTrials":12,"cells":3086},"Brexpiprazole ODT 2mg with water",{"EARLY_PHASE1":3087,"PHASE1":3089,"PHASE2":3101,"PHASE3":3103,"PHASE4":3105,"NA":3107},{"trials":3088,"activeCount":93},[],{"trials":3090,"activeCount":93},[3091],{"nctId":3092,"briefTitle":3093,"status":101,"phases":3094,"primaryCompletion":3095,"completion":3095,"start":3096,"enrollment":3037,"conditions":3097,"interventions":3098},"NCT03902574","Bioequivalence Study of Brexpiprazole Orally Disintegrating Tablets (ODT) 2mg",[83],"2019-06-18","2019-03-27",[814],[3085,3099,3100],"Brexpiprazole ODT 2mg without water","Brexpiprazole conventional tablet 2mg",{"trials":3102,"activeCount":93},[],{"trials":3104,"activeCount":93},[],{"trials":3106,"activeCount":93},[],{"trials":3108,"activeCount":93},[],{"intervention":3099,"totalTrials":12,"cells":3110},{"EARLY_PHASE1":3111,"PHASE1":3113,"PHASE2":3119,"PHASE3":3121,"PHASE4":3123,"NA":3125},{"trials":3112,"activeCount":93},[],{"trials":3114,"activeCount":93},[3115],{"nctId":3092,"briefTitle":3093,"status":101,"phases":3116,"primaryCompletion":3095,"completion":3095,"start":3096,"enrollment":3037,"conditions":3117,"interventions":3118},[83],[814],[3085,3099,3100],{"trials":3120,"activeCount":93},[],{"trials":3122,"activeCount":93},[],{"trials":3124,"activeCount":93},[],{"trials":3126,"activeCount":93},[],{"intervention":3100,"totalTrials":12,"cells":3128},{"EARLY_PHASE1":3129,"PHASE1":3131,"PHASE2":3137,"PHASE3":3139,"PHASE4":3141,"NA":3143},{"trials":3130,"activeCount":93},[],{"trials":3132,"activeCount":93},[3133],{"nctId":3092,"briefTitle":3093,"status":101,"phases":3134,"primaryCompletion":3095,"completion":3095,"start":3096,"enrollment":3037,"conditions":3135,"interventions":3136},[83],[814],[3085,3099,3100],{"trials":3138,"activeCount":93},[],{"trials":3140,"activeCount":93},[],{"trials":3142,"activeCount":93},[],{"trials":3144,"activeCount":93},[],{"intervention":3146,"totalTrials":12,"cells":3147},"OPC-14597 IMD",{"EARLY_PHASE1":3148,"PHASE1":3150,"PHASE2":3159,"PHASE3":3161,"PHASE4":3163,"NA":3165},{"trials":3149,"activeCount":93},[],{"trials":3151,"activeCount":93},[3152],{"nctId":3153,"briefTitle":3154,"status":101,"phases":3155,"primaryCompletion":3156,"completion":3156,"start":880,"enrollment":852,"conditions":3157,"interventions":3158},"NCT02220712","A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia",[83],"2015-04",[15],[3146],{"trials":3160,"activeCount":93},[],{"trials":3162,"activeCount":93},[],{"trials":3164,"activeCount":93},[],{"trials":3166,"activeCount":93},[],{"intervention":3168,"totalTrials":12,"cells":3169},"Brexpiprazole LAI: Dose 1",{"EARLY_PHASE1":3170,"PHASE1":3172,"PHASE2":3186,"PHASE3":3188,"PHASE4":3190,"NA":3192},{"trials":3171,"activeCount":93},[],{"trials":3173,"activeCount":93},[3174],{"nctId":3175,"briefTitle":3176,"status":3177,"phases":3178,"primaryCompletion":3179,"completion":3179,"start":3180,"enrollment":93,"conditions":3181,"interventions":3182},"NCT05119894","A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia","WITHDRAWN",[83],"2021-12-06","2021-11-22",[15],[3168,3183,3184,3185],"Brexpiprazole LAI: Dose 2","Brexpiprazole LAI: Dose 3","Brexpiprazole LAI: Dose 4",{"trials":3187,"activeCount":93},[],{"trials":3189,"activeCount":93},[],{"trials":3191,"activeCount":93},[],{"trials":3193,"activeCount":93},[],{"intervention":3183,"totalTrials":12,"cells":3195},{"EARLY_PHASE1":3196,"PHASE1":3198,"PHASE2":3204,"PHASE3":3206,"PHASE4":3208,"NA":3210},{"trials":3197,"activeCount":93},[],{"trials":3199,"activeCount":93},[3200],{"nctId":3175,"briefTitle":3176,"status":3177,"phases":3201,"primaryCompletion":3179,"completion":3179,"start":3180,"enrollment":93,"conditions":3202,"interventions":3203},[83],[15],[3168,3183,3184,3185],{"trials":3205,"activeCount":93},[],{"trials":3207,"activeCount":93},[],{"trials":3209,"activeCount":93},[],{"trials":3211,"activeCount":93},[],{"intervention":3184,"totalTrials":12,"cells":3213},{"EARLY_PHASE1":3214,"PHASE1":3216,"PHASE2":3222,"PHASE3":3224,"PHASE4":3226,"NA":3228},{"trials":3215,"activeCount":93},[],{"trials":3217,"activeCount":93},[3218],{"nctId":3175,"briefTitle":3176,"status":3177,"phases":3219,"primaryCompletion":3179,"completion":3179,"start":3180,"enrollment":93,"conditions":3220,"interventions":3221},[83],[15],[3168,3183,3184,3185],{"trials":3223,"activeCount":93},[],{"trials":3225,"activeCount":93},[],{"trials":3227,"activeCount":93},[],{"trials":3229,"activeCount":93},[],{"intervention":3185,"totalTrials":12,"cells":3231},{"EARLY_PHASE1":3232,"PHASE1":3234,"PHASE2":3240,"PHASE3":3242,"PHASE4":3244,"NA":3246},{"trials":3233,"activeCount":93},[],{"trials":3235,"activeCount":93},[3236],{"nctId":3175,"briefTitle":3176,"status":3177,"phases":3237,"primaryCompletion":3179,"completion":3179,"start":3180,"enrollment":93,"conditions":3238,"interventions":3239},[83],[15],[3168,3183,3184,3185],{"trials":3241,"activeCount":93},[],{"trials":3243,"activeCount":93},[],{"trials":3245,"activeCount":93},[],{"trials":3247,"activeCount":93},[],{"intervention":3249,"totalTrials":12,"cells":3250},"OPB-51602",{"EARLY_PHASE1":3251,"PHASE1":3253,"PHASE2":3266,"PHASE3":3268,"PHASE4":3270,"NA":3272},{"trials":3252,"activeCount":93},[],{"trials":3254,"activeCount":93},[3255],{"nctId":3256,"briefTitle":3257,"status":101,"phases":3258,"primaryCompletion":1281,"completion":1281,"start":3259,"enrollment":844,"conditions":3260,"interventions":3265},"NCT01344876","Phase I Study of OPB-51602 in Patients With Hematologic Malignancies",[83],"2011-04",[3261,3262,25,3263,3264],"Multiple Myeloma","Non-Hodgkin Lymphoma","Acute Lymphoid Leukemia","Chronic Myeloid Leukemia",[3249],{"trials":3267,"activeCount":93},[],{"trials":3269,"activeCount":93},[],{"trials":3271,"activeCount":93},[],{"trials":3273,"activeCount":93},[],{"intervention":3275,"totalTrials":12,"cells":3276},"nalmefene hydrochloride 10 mg",{"EARLY_PHASE1":3277,"PHASE1":3279,"PHASE2":3290,"PHASE3":3292,"PHASE4":3294,"NA":3296},{"trials":3278,"activeCount":93},[],{"trials":3280,"activeCount":93},[3281],{"nctId":3282,"briefTitle":3283,"status":101,"phases":3284,"primaryCompletion":3285,"completion":3285,"start":3286,"enrollment":3287,"conditions":3288,"interventions":3289},"NCT02679469","A Single-center, Open-label, Single-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Nalmefene 10 mg Tablets in Healthy Japanese Male Subjects",[83],"2016-03","2016-02",7,[1490],[3275],{"trials":3291,"activeCount":93},[],{"trials":3293,"activeCount":93},[],{"trials":3295,"activeCount":93},[],{"trials":3297,"activeCount":93},[],{"intervention":3299,"totalTrials":12,"cells":3300},"Nalmefene Hydrochloride Hydrate",{"EARLY_PHASE1":3301,"PHASE1":3303,"PHASE2":3305,"PHASE3":3307,"PHASE4":3309,"NA":3311},{"trials":3302,"activeCount":93},[],{"trials":3304,"activeCount":93},[],{"trials":3306,"activeCount":93},[],{"trials":3308,"activeCount":93},[],{"trials":3310,"activeCount":93},[],{"trials":3312,"activeCount":93},[3313],{"nctId":3314,"briefTitle":3315,"status":101,"phases":3316,"primaryCompletion":3317,"completion":3318,"start":3319,"enrollment":3320,"conditions":3321,"interventions":3322},"NCT04107051","Post-Marketing Surveillance Study of Nalmefene Hydrochloride Hydrate in Patients with Alcohol Dependence",[],"2023-02-07","2024-02-06","2019-10-01",533,[1490],[3299],{"intervention":3324,"totalTrials":12,"cells":3325},"Abilify prolonged release aqueous suspension for IM",{"EARLY_PHASE1":3326,"PHASE1":3328,"PHASE2":3330,"PHASE3":3332,"PHASE4":3334,"NA":3336},{"trials":3327,"activeCount":93},[],{"trials":3329,"activeCount":93},[],{"trials":3331,"activeCount":93},[],{"trials":3333,"activeCount":93},[],{"trials":3335,"activeCount":93},[],{"trials":3337,"activeCount":93},[3338],{"nctId":3339,"briefTitle":3340,"status":101,"phases":3341,"primaryCompletion":3342,"completion":3343,"start":3344,"enrollment":3345,"conditions":3346,"interventions":3348},"NCT04812379","Specified Drug-use Survey on Abilify Prolonged Release Aqueous Suspension for IM Injection (Prevention of Relapse of Mood Episodes in BP)",[],"2023-09-13","2024-06-21","2021-04-07",535,[3347],"Bipolar Disorder I",[3324],{"intervention":3350,"totalTrials":12,"cells":3351},"Aripiprazole oral product",{"EARLY_PHASE1":3352,"PHASE1":3354,"PHASE2":3356,"PHASE3":3358,"PHASE4":3360,"NA":3362},{"trials":3353,"activeCount":93},[],{"trials":3355,"activeCount":93},[],{"trials":3357,"activeCount":93},[],{"trials":3359,"activeCount":93},[],{"trials":3361,"activeCount":93},[],{"trials":3363,"activeCount":93},[3364],{"nctId":3365,"briefTitle":3366,"status":101,"phases":3367,"primaryCompletion":3368,"completion":3369,"start":3370,"enrollment":3371,"conditions":3372,"interventions":3374},"NCT03179787","Post-Marketing Surveillance Study of Aripiprazole in Patients With Autism",[],"2020-03-17","2020-07-06","2017-04-01",528,[3373],"Autism",[3350],{"intervention":3376,"totalTrials":12,"cells":3377},"OPC-61815 injection 2mg",{"EARLY_PHASE1":3378,"PHASE1":3380,"PHASE2":3382,"PHASE3":3384,"PHASE4":3386,"NA":3388},{"trials":3379,"activeCount":93},[],{"trials":3381,"activeCount":93},[],{"trials":3383,"activeCount":93},[],{"trials":3385,"activeCount":93},[],{"trials":3387,"activeCount":93},[],{"trials":3389,"activeCount":93},[3390],{"nctId":3391,"briefTitle":3392,"status":101,"phases":3393,"primaryCompletion":3394,"completion":3395,"start":3396,"enrollment":3397,"conditions":3398,"interventions":3399},"NCT03254108","Clinical Pharmacology Trial to Investigate the Dose of OPC-61815 Injection Equivalent to Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure",[87],"2018-04-14","2018-04-24","2017-11-06",61,[1102],[3376,3400,3401,3402,3403],"OPC-61815 injection 4mg","OPC-61815 injection 8mg","OPC-61815 injection 16mg","Tolvaptan tablet 15mg",{"intervention":3400,"totalTrials":12,"cells":3405},{"EARLY_PHASE1":3406,"PHASE1":3408,"PHASE2":3410,"PHASE3":3412,"PHASE4":3414,"NA":3416},{"trials":3407,"activeCount":93},[],{"trials":3409,"activeCount":93},[],{"trials":3411,"activeCount":93},[],{"trials":3413,"activeCount":93},[],{"trials":3415,"activeCount":93},[],{"trials":3417,"activeCount":93},[3418],{"nctId":3391,"briefTitle":3392,"status":101,"phases":3419,"primaryCompletion":3394,"completion":3395,"start":3396,"enrollment":3397,"conditions":3420,"interventions":3421},[87],[1102],[3376,3400,3401,3402,3403],{"intervention":3401,"totalTrials":12,"cells":3423},{"EARLY_PHASE1":3424,"PHASE1":3426,"PHASE2":3428,"PHASE3":3430,"PHASE4":3432,"NA":3434},{"trials":3425,"activeCount":93},[],{"trials":3427,"activeCount":93},[],{"trials":3429,"activeCount":93},[],{"trials":3431,"activeCount":93},[],{"trials":3433,"activeCount":93},[],{"trials":3435,"activeCount":93},[3436],{"nctId":3391,"briefTitle":3392,"status":101,"phases":3437,"primaryCompletion":3394,"completion":3395,"start":3396,"enrollment":3397,"conditions":3438,"interventions":3439},[87],[1102],[3376,3400,3401,3402,3403],{"intervention":3402,"totalTrials":12,"cells":3441},{"EARLY_PHASE1":3442,"PHASE1":3444,"PHASE2":3446,"PHASE3":3448,"PHASE4":3450,"NA":3452},{"trials":3443,"activeCount":93},[],{"trials":3445,"activeCount":93},[],{"trials":3447,"activeCount":93},[],{"trials":3449,"activeCount":93},[],{"trials":3451,"activeCount":93},[],{"trials":3453,"activeCount":93},[3454],{"nctId":3391,"briefTitle":3392,"status":101,"phases":3455,"primaryCompletion":3394,"completion":3395,"start":3396,"enrollment":3397,"conditions":3456,"interventions":3457},[87],[1102],[3376,3400,3401,3402,3403],{"intervention":3403,"totalTrials":12,"cells":3459},{"EARLY_PHASE1":3460,"PHASE1":3462,"PHASE2":3464,"PHASE3":3466,"PHASE4":3468,"NA":3470},{"trials":3461,"activeCount":93},[],{"trials":3463,"activeCount":93},[],{"trials":3465,"activeCount":93},[],{"trials":3467,"activeCount":93},[],{"trials":3469,"activeCount":93},[],{"trials":3471,"activeCount":93},[3472],{"nctId":3391,"briefTitle":3392,"status":101,"phases":3473,"primaryCompletion":3394,"completion":3395,"start":3396,"enrollment":3397,"conditions":3474,"interventions":3475},[87],[1102],[3376,3400,3401,3402,3403]]